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Preface 
 
 
This PhD thesis is a part of a multidisciplinary project developed in collaboration with Dr. Paolo 
Costantino (Novartis Vaccine and Diagnostics). 
 
An evaluation process for patent purpose is currently in progress. Thereafter, at least three 
manuscripts (concerning the synthesis of oligomers, NMR studies and glycoconjugations) will be 
submitted for publication. 
 
Figures, tables, molecules, schemes, and literature numerations are not contiguous, each chapter 
has its own numbering. 
 
The full structural characterization (MS, 1H-NMR, 13C-NMR and, when relevant 31P-NMR) of new 
products are reported. Some NMR spectra are incorporated for a better understanding of the 
described results. All the products are completely characterized in CHAPTER 9 (Experimental 
Section). 
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APC Antigen Presenting Cell 
BCG Bacillus Calmette-Guérin 
BCR B cell receptor 
BSA Bovine Serum Albumin 
CDAP 1-Cyano-4-dimethylamino-pyridinium tetrafluoroborate 
CPS Capsular polysaccharide 
CRM197 Cross-Reacting Material 197 
CTL Citotoxic T Lymphocytes (or CD8+ T cells) 
DC Dendritic Cell 
DCC Dicyclohexyl carbodiimide  
DCM Dichloromethane 
ELISA Enzyme-linked immunosorbent assay 
Glcp Glucopyranosyl 
Hib Haemophilus influenzae type b 
HIV Human Immunodeficiency Virus 
HSA Human Serum Albumin 
IgG ab high affinity antibodies 
IgM ab low affinity antibodies 
KLH Keyhole Limpet Hemocyanin 
LPS Lipopolysaccharide 
MenA N. meningitidis type A 
MenX N. meningitidis type X 
MHC Major Histocompatibility Complex 
MPL A Monophosphoryl Lipid A 
NAc N-Acetyl 
NMR Nuclear Magnetic Resonance 
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PAMP Pathogen-Associated Molecular Patterns 
PRR Pattern-Recognition Receptor 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
QS-21 saponin extracted from Quillaja saponoria 
TACA Tumor-Associated Carbohydrate Antigen 
TCR T-cell Receptor 
Th helper T cells (or CD4+ T cells) 
TLR Toll-Like Receptor 
TPS-Cl 2,4,6-Triisopropylbenzenesulfonyl chloride 
TPS-NT 3-Nitro-1-(2,4,6-triisopropylbenzenesulfonyl)-1,2,4-triazole 
TT Tetanus Toxoid 
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Ac Acetyl 
 
Bn Benzyl 
 
BS(PEG)5 Bis-succinimidyl penta-ethylene glycol 
 
Cbz Carbobenzyloxy 
 
DCM Dichloromethane CH2Cl2 
DMAP 4-Dimethylaminopyridine 
 
DMF Dimethylformamide 
 
Et Ethyl  
Me Methyl  
Ph Phenyl 
 
PivCl Trimethylacetyl chloride, or Pivaloyl chloride 
 
Py Pyridine 
 
TEA Triethylamine 
 
TBAI Tetra-n-butylammonium iodide 
 
TBAF Tetra-n-butylammonium fluoride 
 
TEAB Triethylammonium bicarbonate 
 
TDS Thexyldimethylsilyl  
 
TFA Trifluoroacetic acid 
 
TfN3 Trifluoromethanesulfonyl Azide 
 
Tf2O Trifluoromethanesulfonic Anhydride 
 
THF Tetrahydrofuran 
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Glycoimmunobiology is an emerging field. Immunology and glycobiology are connected by a two-
way street: the immune response is linked to glycobiology by recognizing carbohydrates as 
antigens, on the other hand in glycobiology glycans influence multiple levels of the immune 
response.1 
THE IMMUNE SYSTEM 
Before being adopted by scientific community, the term immunity was used in legal field. 
Immunity is an exemption from a burden, an obligation or a duty. The term immune derives from 
the Latin word immunitas, “inmunitas” from the archaic munus, meaning office, duty, assignment 
and performance.  “Immunitas” was commonly used by Romans to suggest the dispensation from 
an activity, taxes or military service. 
 “Druides a bello abesse consuerunt neque tributa una cum reliquis pendunt. Militiae vacationem 
omniumque rerum habent immunitatem.” 
Gaius Julius Caesar 
(Commentaries on the Gallic War, book 6, par.14). 
In the middle of 19th century, its meaning was extended to persons “except from” or protected 
against something, so to be immune. The term immune system refers to a collection of 
mechanisms that protects against foreign substances  by identifying and killing invading 
pathogens. 
The immune system is amazingly complex: it is a network of cells (Figure 1), tissues, and organs 
that work together to defend the body against attacks by foreign invaders. 
 
Figure 1_Cells of the Immune System. 
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These are primarily microbes—tiny organisms such as bacteria, parasites, and fungi that can cause 
infections. Viruses also cause infections, but are too primitive to be classified as living organisms. 
The human body provides an ideal environment for many microbes. It is the immune system’s job 
to keep them out or, failing that, to seek out and destroy them. 
IMMUNE RESPONSE 
Antigen is any molecule perceived by the immune system as foreign invader or simply potentially 
dangerous for the host. The immune system responds to antigens by eliciting a proper immune 
response. More specifically, protective immunity against pathogen exposure is achieved by the 
integration of two distinct arms of the immune response, the innate and adaptive (antigen-
specific) responses. The immune response comprises different steps. First, physical barriers, i.e. 
skin in humans, prevent pathogens  from entering in the body.2 But then, if a pathogen is able to 
cross them, the innate system, founded both in plants and animals, acts quite immediately in a 
non-specific manner.3 A third level of protection, the adaptive system, can be activated if the 
pathogens impedes the innate system. In the case of adaptive system, the immune response 
retains a “memory” of the pathogen, so that the immune response works faster and stronger each 
time that a specific pathogen is encountered. 
INNATE IMMUNITY AND ADAPTIVE IMMUNITY 
The innate response is rapid and aspecific, it is mediated by antigen presenting cells (APCs) and 
establishes the first line of immune defence. It acts during the early stages of infection (within 
minutes), detecting and responding to pathogen-associated molecular patterns (PAMPs), which 
are structurally and chemically diverse compounds highly conserved in pathogens and absent in 
their multicellular host. 
By contrast, the adaptive response, which is mediated by B and T lymphocytes, recognizes 
pathogens with high affinity, providing the fine antigenic specificity required for complete 
elimination of the infective agent and the generation of the immunological memory. However, the 
establishment of adaptive immunity typically takes days to weeks to become effective. 
APCs (and in particular dendritic cells, DCs) provide a crucial bridge between the two responses. 
APC surface is plenty of pattern-recognition receptors (PRRs), including the recently discovered 
Toll-like receptor family (TLRs), that can recognize a huge variety of PAMPs. PRRs stimulation 
creates the necessary pro-inflammatory context (expression of costimulatory molecules and 
secretion of soluble cytokines and chemokines) leading to full maturation of DCs, antigen uptake 
and intracellular processing (Figure 2a). Mature DCs migrate to the draining lymph nodes where 
they prime naive T cells, thus triggering and amplifying the adaptive arm of the immune response. 
The crucial event of the T cells activation-differentiation process is the immunological synapse, 
initiated by formation of a ternary complex MHC (major histocompatibility complex, class I or II, on 
DC surface) antigen T cell receptor (TCR) on T cell surface, followed by further specific interactions. 
Depending on the antigen exposed on DC surface, the immunological synapse may induce the 
activation of cytotoxic T lymphocytes (CTL, or CD8+ T cells, in case the antigen is presented by 
MHC class I), effector T cells that destroy target cells infected by intracellular viruses or bacteria, 
and/or the proliferation of helper T cells (Th, or CD4+ T cells, in case the antigen is presented by 
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MHC class II). In turn, activated Th cells elicit a conventional T cell-dependent immune response by 
interacting with resting B cells via MHC class II and driving their proliferation and differentiation 
into plasma cells (antibody-forming cells, mainly producing low affinity IgM-type antibodies) and 
memory B cells. Contrary to plasma cells, memory B cells survive for a long time in the body and 
respond rapidly to subsequent exposures of antigen by secreting high affinity IgG antibodies. 
 
Figure 2_Diagramatic representation of the immune response. 
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GLYCOBIOLOGY 
In 1988 the term glycobiology was first used to describe the merging of the traditional disciplines 
of carbohydrate chemistry, biochemistry, and cell biology.4 However, almost a century earlier, the 
experiments on biologically important sugars performed by Emily Fischer predated the recognition 
of glycobiology as a distinctive field of investigation. 
CARBOHYDRATE ANTIGENS 
Amongst human pathogens, there is a large number of bacterial species which causes serious 
public health concerns. The surface of bacterial pathogens is covered with a dense array of oligo- 
and polysaccharides that, besides conferring mechanical stability to the cell membrane of 
microorganisms, are crucial protective antigens and virulence factors. 
The polysaccharide surface can be in the form of capsules, glycoproteins or glycolipids. In Gram-
negative bacteria, the lipopolysaccharide (LPS) also referred to as endotoxin, covers ca. 40% of the 
bacterial surface. The capsular polysaccharides (CPS) may be present in both Gram-negative 
bacteria such as N. meningitidis, Haemophilus influenzae, E. coli or Salmonella typhi and in Gram-
positive such as Streptococci and Staphylococci, while, the glycolipid LPS is only present in Gram-
negative bacteria and is part of the outer membrane. It is built of a lipid part and a polysaccharide 
part. The polysaccharide can be divided in a core oligosaccharide proximal to the lipid part and an 
O-polysaccharide. The O-polysaccharide is, like the CPS, either a homopolymer (Vibrio cholerae 
O1, Brucella abortus, B. melitensis) or made up from repeating units which may be di- to 
hexasaccharides.  
HYSTORY 
Historically, the first example of carbohydrate antigens dates back to 1900 in the form of ABO(H) 
blood group antigens.5 The ABO blood group system is widely credited to have been discovered by 
the Austrian scientist Karl Landsteiner, who found three different blood types:6 he was awarded 
the Nobel Prize in Physiology or Medicine in 1930 for his work. 
In 1917 a “specific soluble substance” secreted by pneumococci during growth was discovered by 
Dochez and Avery.7 They showed that there was present in the fluid media of pneumococcus 
cultures a substance which precipitated specifically in antipneumococcus serum of homologous 
type. Further work by Heidelberger and Avery has shown that two specific substances 
could be isolated from Types I, II, and III pneumococci; namely, a species specific protein and a 
type specific polysaccharide. 
These are the first examples in which any material other than protein have displayed antigenic 
properties. 
Between 1920s and 1930s the immunological properties of bacterial CPSs became the target of 
several scientists: it was well known that an immune response against the surface polysaccharides 
confers protection against the disease.8 In the mid-1940s it was evident that CPS elicited type-
specific protective immune responses, and unfortunately infants and young children did not 
respond with type-specific antibodies; moreover that type-specific antibodies conferred 
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protection and vaccination with polysaccharides reduced the carrier rate of bacteria of the same 
types as in the vaccine. An important discovery regarded the coming of “glycoconjugates”, using 
oligosaccharides covalently linked to a carrier protein.9 On the basis of rabbits experiments, it was 
found that neo-glycoconjugates were able to induce high titred antibody responses which were, 
boostable and protective against challenge infection. 
IMMUNE RESPONSE TO POLYSACCHARIDES 
While most antigens, especially proteins and derivatives, are T dependent immunogens, i.e. they 
induce T cell activation via a MHC II-restricted pathway, the immune response to polysaccharides 
is typically T cell-independent. Owing to their polymeric structure, polysaccharides bind 
simultaneously several B cell receptors (BCR) leading to direct activation of B cells without T cells 
cooperation (Figure 2b).10 As a result, the immune response to carbohydrates is hallmarked by an 
exclusive primary immune response with low affinity IgM production and no class switch to high 
affinity IgG antibodies. Moreover, pure polysaccharides cause immune responses of relatively 
short duration, and they do not induce immunological memory, i.e. they fail to result in a booster 
effect. T cell independent polysaccharides can be converted into T cell dependent immunogens by 
their covalent attachment to carrier proteins. The protein carrier incorporates T cell epitope 
peptides, which facilitate uptake and processing of the glycoconjugate by APC enhancing the 
presentation of the carbohydrate antigen for helper T cells activation. In this way immunological 
memory is established, raising a strong, durable and protective immune response from early 
childhood. Typical examples of immunogenic carrier proteins include bovine serum albumin (BSA) 
or its human variant HSA, keyhole limpet hemocyanin (KLH), bacillus Calmette-Guérin (BCG), 
CRM197 (Cross-Reacting Material 197), and tetanus toxoid (TT). 
Furthermore, in order to achieve an optimal host protection, a vaccine setting should include a 
component (adjuvant) able to amplify the immune response. In particular, since saccharide 
antigens are often poorly immunogenic, carbohydrate-based vaccines need adjuvants to improve 
their efficiency and the quality and specificity of the immune response. Typical immunoadjuvants 
widely employed in vaccine settings are complete and incomplete Freund’s adjuvants,11 Detox, QS-
21 (a saponin extracted from the bark of the Quillaja saponoria tree), and monophosphoryl lipid A 
(MPLA). However, the administration of these strong immunoactive species may cause undesired 
side effects, and milder and safer lipopeptide-based immunoadjuvants have been employed in 
many vaccine candidates.  
Adjuvants are perceived as “danger signals” after binding to PRRs, and stimulate the activation 
and maturation process of APCs, thus enhancing the speed and duration of both the innate and 
adaptive immune response. In particular, adjuvants function as immune potentiators, providing 
the pro-inflammatory context necessary for optimal antigen-specific immune activation and 
amplifying the innate immune response. After the discovery of the TLR family, it has been shown 
that many PAMPs, as well as synthetic adjuvants, activate DCs upon stimulation of a specific TLR. 
These findings suggested that TLRs are essential in linking innate and adaptive immunity 
throughout the entire course of the host defence response, since they are involved in multiple 
immunostimulatory activities. Therefore, TLRs can be defined as general adjuvant receptors in the 
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body. On the other hand, adjuvants may also act as delivery systems to localize vaccine 
components and to target them to APCs. 
CARBOHYDRATES AND PATHOGENS: ENCAPSULATED BACTERIA 
BACTERIAL CELL STRUCTURE 
Bacteria, despite their simplicity, contain a well-developed cell structure which is responsible for 
many of their unique biological properties. Because of the simplicity of bacteria relative to larger 
organisms and the ease which they can be manipulated experimentally with, the cell structure of 
bacteria has been well studied. 
The most elemental structural property of bacteria is cell morphology (shape): typical examples 
(exemplified in Figure 3) are coccus (spherical), bacillus (rod-like), spirillum (spiral) and 
filamentous. Cell shape is often the first characteristics observed by a microbiologist to determine 
the identity of an unknown bacterial culture, moreover the Gram’s method, based on chemical 
and physical properties of cell walls, allows to differentiate bacterial species as gram-positive and 
gram-negative. 
 
Figure 3_Bacterial cell morphology. 
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Gram staining is a laboratory technique used to detect peptidoglycan (cross-linked multilayered 
polysaccharide-peptide complex), which is present outside the lipid cell membrane: those that 
retains gram stain are called gram-positive, the others, that do not, are gram-negative. A gram-
positive results in a purple/blue colour while a gram-negative in a pink/red colour. 
In comparison to eukaryotes, the intracellular features of the bacterial cell are extremely simple. 
Bacteria do not contain organelles in the same sense as eukaryotes. Instead, the chromosome and 
perhaps ribosomes are the only easily observable intracellular structures found in all bacteria. 
Unlike eukaryotes, the bacterial chromosome is not enclosed inside of a membrane-bound 
nucleus but instead resides inside the bacterial cytoplasm. This means that the transfer of cellular 
information through the processes of translation, transcription and DNA replication all occur 
within the same compartment and can interact with other cytoplasmic structures, most notably 
ribosomes. In most bacteria the most numerous intracellular structure is the ribosome, the site of 
protein synthesis in all living organisms. They do exist, however, specialized groups of bacteria that 
contain more complex intracellular structures.  
ENCAPSULATED BACTERIA 
Encapsulated bacteria, both gram positive and gram negative, possess a polysaccharide coat 
(capsule, Figure 4) surrounding the bacterial cell and that is essential for their pathogenicity, 
exerting a protective function against the host’s immune defence.  
 
Figure 4_Bacterial, Gram-positive and Gram-negative, cells exemplification. 
As a result, infectious diseases from encapsulated bacteria are still the third leading cause of death 
in the world. A large body of literature data indicates that carbohydrate-specific antibodies are 
predominantly responsible for protection against bacteria (N. meningitidis, Haemophilus 
influenzae, Escherichia coli, Salmonella typhi, and Staphilococcus aureus) with either a capsule or 
lipopolysaccharide on their surface, suggesting that vaccines consisting of purified pathogen-
associated saccharide antigens may be effective to confer protection against infectious diseases. 
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In spite of the increased knowledge in immunology, there are several problems that remain to be 
solved: 
 the base of serogrouping or serotyping systems is due to the structural differences in the 
CPS, so that carbohydrate antigens exhibit a large degree of antigenic variation.  
 homology between carbohydrate structures present on bacterial surface and those of host 
cell membranes have been reported: i.e. the N. meningitidis serogroup B CPS, as well as the 
E. Coli K1 antigen, are antigenically similar to structures expressed on human foetal neuronal 
cells and consequently, poor immunogens in humans.12 Therefore, the use of N. meningitidis 
serogroup B CPS in a vaccine has the potential risk of inducing autoantibodies.10 
 polysaccharide antigens are mostly poor immunogens (T-independent antigens).13 Children 
below 2 years of age and elderly respond poorly to olysaccharide antigens.  
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About plague of Athens, 430 BC 
 “Epidemic doesn’t strike twice: or, at least, the potential relapse is not deadly”. 
Thucydides 
(History of the Peloponnesian War, book 2, par.51) 
INTRODUCTION 
The Plague of Athens was a devastating epidemic which hit the city-state of Athens in ancient 
Greece during the second year of the Peloponnesian War (430 BC). Athens lost perhaps one third 
of the people sheltered within its walls. Historians have long tried to identify the disease behind 
the named Plague of Athens (plague, smallpox, or typhoid fever). Given the possibility that 
symptoms of a known disease may have mutated over time, or that the epidemic was caused by a 
disease which no longer exists, the exact nature of the Athenian epidemic may never be known. 
But, Thucydides himself suffered the illness, and survived: survivors could nurse sick person 
without falling again sick. This is the first example of acquired immunity. 
HISTORY OF VACCINATION 
Not only in Greece, but epidemics were well known in the ancient world. The smallpox virus 
(caused by either of two virus variant, Variola major and Variola minor) appeared in Africa during 
10000 BC and is also known by the Latin name Variola, derived “varius”, meaning spotted, or 
“varus”, meaning pimple. The earliest physical evidence of smallpox is probably the pustular rash 
on the mummified body of Pharaoh Ramses V of Egypt. 
During the whole human history, smallpox epidemics came one after the other with regularity and 
constancy. The earliest procedure used to prevent smallpox was inoculation (also known as 
variolation). Inoculation was possibly practiced in India as early as 1000 BC, and involved either 
nasal insufflation of powdered smallpox scabs, or scratching material from a smallpox lesion into 
the skin. However, the idea that inoculation originated in India has been challenged as few of the 
ancient Sanskrit medical texts described the process of inoculation. Accounts of inoculation 
against smallpox in China can be found as early as the late 10th century, and the procedure was 
widely practiced by the 16th century, during the Ming Dynasty. Lady Mary Wortley Montagu 
observed smallpox inoculation during her stay in the Ottoman Empire, writing detailed accounts of 
the practice in her letters, and enthusiastically promoted the procedure in England upon her 
return in 1718. In 1721, Cotton Mather and colleagues provoked controversy in Boston by 
inoculating hundreds. 
In 1796, Edward Jenner1, a doctor in Berkeley, Gloucestershire, rural England, discovered that 
immunity to smallpox could be produced by inoculating a person with material from a cowpox 
lesion. Cowpox is a poxvirus in the same family as variola. Jenner called the material used for 
inoculation vaccine, from the root word “vacca”, which is Latin for cow.  
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Figure 1_ (James Gillray, 1802) Caricature of Jenner vaccinating patients. 
The procedure was much safer than variolation, and did not involve a risk of smallpox 
transmission. Vaccination to prevent smallpox was soon practiced all over the world. In the end of 
19th century other pathogenic diseases were rampant, but Jenner’s method didn’t work with 
them. 
In 1858, the French chemist Louis Pasteur demonstrated that fermentation is caused by the 
growth of micro-organisms, and that the emergent growth of bacteria in nutrient broths is not due 
to spontaneous generation (Omne vivum ex vivo "all life is from life"): infections caused by germs 
came from outside into the human body. After that the deaths due to infection drastically 
decreased by washing with disinfectants hands and/or surgical instruments. 
Pasteur's later work on diseases included work on chicken cholera. During this work, a culture of 
the responsible bacteria had spoiled and failed to induce the disease in some chickens he was 
infecting with the disease. Upon reusing these healthy chickens, Pasteur discovered that he could 
not infect them, even with fresh bacteria; the weakened bacteria (without feeding they were 
deadened) had caused the chickens to become immune to the disease, even though they had 
caused only mild symptoms.  
The notion of a weak form of a disease causing immunity to the virulent version was not new; this 
had been known for a long time for smallpox and Jenner’s immunization. In Pasteur experiment 
the novelty was that weakened disease can’t be found in nature: human intervention had 
determined the restricted virulence of bacteria. Pasteur gave these artificially weakened diseases 
the generic name of vaccines, in honour of Jenner's discovery. Pasteur produced the first vaccine 
for rabies by growing the virus in rabbits, and then weakening it by drying the affected nerve 
tissue. 
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For a century, Vaccine developers have followed Pasteur’s rules: 
 Jonas Salk developed a vaccine containing a poliovirus (killed by treatment with 
formaldehyde); 
 Albert Sabin used an attenuated, by in vitro purifications, poliovirus. 
 vaccines against measles, mumps, and rubella were pioneered by Hilleman; 
 Ramon (1924) and Glenny (1923) laid the fundamentals for the development of vaccines 
against diphtheria and tethanus, N. meningitidis, Streptococcus pneumoniae, Haemophilus 
influenzae, and others diseases: they isolated and inactivated essential components of 
bacteria and viruses. 
At the end of 20th century, many vaccines have been designed and new technologies, such as 
recombinant DNA and chemical conjugation between sugars and carrier proteins, have 
contributed to the evolution of the traditional technologies with the aim of conquer the remaining 
pathogens. But an important new technology, reverse vaccinology, become available to scientists 
after the discovery of microbial genomes. 
IMMUNISATION 
Immunity to infectious microorganisms can be achieved by active or passive immunization, and 
acquired either by natural (transfer from mother to foetus or previous infection) or artificial 
(injection of antibodies or vaccine) processes. 
Antibodies from humans or animals, specific for a pathogen or toxin, are transferred to non-
immune individuals when there is a risk of infection and the body have no time to develop own 
immune response: passive immunization is induced artificially, but it can occur also naturally by 
transfer of maternal antibodies to the foetus through placenta. This method acts quickly but is 
short-lasting, because the antibodies are naturally broken down. 
The introduction of a foreign molecule (microbe or parts of it) into the body causes the body itself 
to generate immunity against the target. Active immunization allows immunologic memory and 
can be achieved by infection with a microorganism or be acquired by administration of a vaccine. 
Active immunity is generally long-term and invokes B cells proliferation and T cells activation. 
TYPE OF VACCINES 
There are several approaches to design vaccines against microbes. These choice are based on 
information about the type of microbe, for instance how it infects cells or how the immune system 
responds to it, or on the regions of the world where it has to be used. 
The type of vaccines currently in use are: 
 live, attenuated vaccines; 
 inactivated vaccines; 
 subunit vaccines; 
 toxoid vaccines; 
 conjugated vaccines; 
 DNA vaccines; 
 recombinant vector vaccines. 
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Microbes can be attenuated and weakened in laboratory. Loosing their ability to cause a disease, 
live-attenuated vaccines are similar to a natural infection and they are “good teacher” of immune 
system: with only few doses they are able to confer long-life immunity by eliciting a strong 
immune response. The most important disadvantage of this kind of vaccines lie in their nature: 
they are still “alive” and so they could change or mutate so that could revert in virulent form and 
cause disease. Moreover people who have damaged or weakened immune system cannot receive 
this kind of treatment. Another limitations are: 
 storage: they need to be freezing to maintain the efficacy and it’s a problem for transport 
especially by long travel (in developing countries it could be not the best choice); 
 easy to create for certain viruses (containing a small number of genes), but very difficult to 
create for bacteria (having thousands of genes they are much harder to control). 
Chemicals, heating, or radiations are the common procedure to create inactivated vaccines. In this 
case the microbe can’t mutate because it’s dead. In contrast with live-attenuated vaccines, 
inactivated vaccines can be easily stored and transported because they don’t need refrigeration, 
which make them suitable for developing countries. Unfortunately they are not able to stimulate a 
strong immune response, and several doses are required. 
Subunit vaccines (i.e. Hepatitis B virus) are based on the essential antigens (and not on the entire 
microbe) that best stimulate the immune system. Essential antigens are identified by a time-
consuming and tricky process consisting in: 
 to grow the microbe in lab and then use chemicals to break it; 
or 
 to build antigen molecules from the entire microbe using a recombinant DNA approach (this 
vaccines are called recombinant subunit vaccines). 
Toxoid vaccines are designed in the case of bacteria can secrete toxins that is the main cause of 
disease. Toxoids, inactivated toxins by formalin, are safe for use as vaccines (i.e. diphtheria and 
tetanus). 
If the scientist knows and is able to analyze all the genes of a microbe, a DNA based vaccine can be 
a solution to the disease. DNA based vaccines are still in experimental stages, but to use codifying 
genes for important antigens show a great promise: in fact, they are easy and inexpensive to 
construct, moreover they couldn’t cause disease because they are just copies of genes, not 
containing the microbe. 
Recombinant Vector vaccines are similar to DNA vaccines: “vector” is the microbe used as carrier 
to introduce microbial DNA to cells into the body. This kind of vaccines are currently under 
investigation and by the moment are used for HIV (human immunodeficiency virus), rabies and 
measles. 
The virulence of some pathogenic bacteria depends on the non-pathogenic properties of their 
outer coating, a capsule made of polysaccharides. Since capsular polysaccharides (CPSs) are the 
key virulence factors for encapsulated bacteria, various CPS-based antibacterial vaccines have 
been developed and introduced in the market. However, as polysaccharides are T-independent 
antigens, purified CPS-based vaccines are poorly immunogenic in infants and young children, and 
they fail to establish immunological memory. A key breakthrough in this field was the introduction 
of glycoconjugate vaccines, where the CPSs (or their synthetic fragments) are conjugated to carrier 
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proteins, thus eliciting a T-dependent response which enhances the immunogenic properties of 
the saccharide moiety. In this way, boosting of the antibody response occurs on reimmunisation 
and immunological memory is established. In 1945 the immunization with specific CPS, to prevent 
pneumococcal pneumonia, was the first example of polysaccharide vaccine.2 Vaccines currently 
present on the market are based on this concept. 
REVERSE VACCINOLOGY3 
If the genome of a pathogen is accessible, the vaccine design could be rationalized by computer 
using the informations present in its genome, without the need to grow the specif microbe. This 
process is called “reverse vaccinology”. 
The genomic information was first used for the development of a vaccine against serogroups B 
meningococcus,4 and moreover the ability to interrogate the entire antigenic repertoire has 
implemented the power of this technique. In principle the reverse vaccinology takes into account 
the entire protein repertoire of each pathogen to select the best candidate antigen. 
In Table 1 is reported a comparison between the conventional vaccination and the reverse 
vaccinology. 
Table 1
a
_Traditional vaccinology vs. Reverse vaccinology. 
 TRADITIONAL VACCINOLOGY REVERSE VACCINOLOGY 
ANTIGENS AVAILABLE 
10-25 identified by biochemical or 
genetic tools. 
Virtually all antigens encoded by 
the genome. 
PROPERTY OF ANTIGENS 
The most abundant antigens, the 
most immunogenic during 
disease, only from cultivable 
microorganism. 
All antigens are available, even if 
not highly immunogenic during 
disease. Antigens from 
noncultivable microorganisms can 
be identified. 
IMMUNOLOGY OF THE ANTIGENS 
Highly immunogenic antigens, 
often variable in sequence, 
because of immune selective 
pressure. Some may contain 
domains mimicking self-antigens 
and may induce autoimmunity. 
The most conserved protective 
antigens can be identified. Usually 
they are not the most 
immunogenic during infection. 
The novel antigens are screened 
against the human genome, and 
antigens with homology to self-
antigens are removed upfront. 
POLYSACCHARIDE ANTIGENS 
A major target of traditional 
bacterial vaccines. 
Cannot be identified by reverse 
vaccinology. But novel 
carbohydrate antigens can be 
discovered by the identification of 
operons coding for the 
biosynthesis of polysaccharides. 
T CELL EPITOPES 
Known epitopes limited to the 
known antigens. 
Virtually every single T cell 
epitope is available. Screening of 
the total T cell immunity can be 
done by overlapping peptides. 
a
 Extracted from ref. 3. 
“Synthesis and conjugation of Neisseria Meningitidis X Capsular Polysaccharide Fragments“ 
Carbohydrate-based vaccines 
 
 
C
H
A
P
TE
R
 2
: G
LY
C
O
C
O
N
JU
G
A
TE
 V
A
C
C
IN
ES
 , 
20 
 
GLYCOCONJUGATE VACCINES5,6 
As introduced in CHAPTER 1, in 1929 Avery and Goebel found out the solution to the weaker sugar 
antigens: their chemo-immunological studies included the immunological specificity of synthetic 
sugar-protein antigens. They demonstrated that non-immunogenic derivatives of glucose and 
galactose were able to induce proliferation of antibodies in rabbit only if conjugated to proteins.7 
Indeed, the combination of a microbial poly- or oligosaccharide (weak antigen, B-cell epitopes) 
with a carrier protein (T-cell epitopes) generates a conjugate vaccine, thus increasing in quantity 
and quality the immunogenicity of sugar-based antigens. 
Bacterial conjugate vaccines currently in use are based on three steps synthesis: 
 fermentation, followed by purification, leads to pure bacterial polysaccharides; 
 fermentation, and purification by formaldehyde lead to purified toxins (i.e. tetanus toxoid 
(TT) or diphtheria toxins are the most used); 
 the conjugation of the pure bacterial polysaccharide with a toxin, by chemical methods, 
allows the formation of a covalent bond between the two components. 
The functional groups used to create this bond (Table 2) could be intrinsic to the polysaccharide 
and the protein.8  Protein-saccharide conjugation can be achieved by site selective chemical 
modification of the sugar chain, for example by introduction of a thiol or a carboxylic group at the 
reducing end.9 
Alternatively, the efficiency and speed of conjugation can be improved by the insertion of a spacer 
arm on the sugar chain suitable for protein conjugation (single point attachment).10 The 
introduction of a spacer can relieve the steric hindrance between the two moieties, and moreover 
it allow an easier coupling step. Then, the spacer has to be “immunologically silent”: it means that 
no component of the linker should induce high titres of linker-specific antibodies. 
CONSIDERATIONS ON THE IMMUNOGENICITY OF CONJUGATED VACCINES 
Different issues can influence the immunogenicity of conjugated vaccines:11 
i. the size of the saccharide chain; 
ii. O-acetylation degree of the carbohydrate; 
iii. the loading: sugar/protein ratio; 
iv. the nature and the length of the spacer; 
v. the nature of the protein carrier. 
SACCHARIDE MOIETY: SIZE AND SUGAR/PROTEIN RATIO 
In 1989 the first evaluation of the size and chemistry effects on immunogenicity has been 
accomplished by Seppala and co-workers.11e There is not a rule that can determine what is the 
proper number of repeating units of saccharide, and the best sugar/protein ratio for a better 
conjugation. In principle, less than four repeating units are not enough to establish immune 
response. The influence of the sugar/protein ratio is different for antigens of variable length. 
In general, the immunogenicity can increase with the molecular size of the polysaccharide and also 
of the conjugates. 
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Table 2_Examples of functional groups used in chemical conjugation. 
CDAP = 1-Cyano-4-dimethylamino-pyridinium tetrafluoroborate 
SPACER’S NATURE 
Also the nature of the spacer is correlated to immunogenicity problems. Rigid constrained spacer, 
i.e. cyclic structure, such as maleimido, are known to drive the immune response away from the 
sugar target, because of the formation of considerable amounts of undesirable antibodies. A 
flexible spacer, i.e. alkyl type, resulted as non-immunogenic. 
CARRIER PROTEINS COMMONLY USED 
In first attempts, Diphtheria and TTs toxins families have been used for conjugate vaccines 
preparation, but in general a large number of protein carriers has been evaluated as suitable for 
conjugate vaccines.19 Keyhole limpet hemocyanin (KLH) and the virus-like particle Qβ were also 
CHEMISTRY FUNCTIONAL GROUPS INVOLVED PRODUCTS 
Carbodiimide-mediated 
condensation 
  
Active ester 
 
 
Reductive amination 
 
 
Thioalkylation12 
  
Thiol addition13 
  
Disulfide formation14  
 
Thiol-ene15,16  
 
Cyanogen bromide or CDAP 
activation 
  
Oxime formation17 
 
 
“Click Chemistry”18  
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used.20 CRM197,
21 a non toxic (so it doesn’t need detoxification by formaldehyde) mutant of 
diphtheria toxin, has been extensively used for preparation of licensed vaccines. 
In principle, the preferable features for a carrier are: 
 high level of purity; 
 high level of safety; 
 the possibility to be fully characterized by physicochemical methods; 
 ability to induce a strong T-cell help; 
 low antibody response to carrier-specific B-cell epitopes, in order to drive the response 
against sugar moiety.  
SYNTHETIC APPROACHES 
Since the synthesis of conjugate vaccins is commonly accomplished by extraction and subsequent 
purification of poly- or oligosaccharides from natural capsule of microbial culture, two significant 
drawbacks can’t be avoided: 
 microbial contamination: traces of bacterial contaminants, such as endotoxins; 
 heterogeneity: coexistence of CPS fragments of different sizes. 
Moreover, in particular cases (fungal antigens, viral oligosaccharides, tumor-associated 
carbohydrate antigens (TACAs)) it’s not easy to extract carbohydrate antigens from biological 
sources, while in other cases they can’t be obtained at all.  
Thus, the overcoming of these disadvantages is constituted by the application of the fully synthetic 
approach. 
In 1975 Lemieux’s group22 pioneered the first attempts on fully synthetic oligosaccharide 
conjugates, while Bencomo13 and co-workers developed the first fully synthetic conjugate vaccine. 
The chemical synthesis of CPS fragments of different length leads to: 
 provide homogeneous, well defined and characterized fragments; 
 obtain fragments that were not accessible by extraction from microbial cultures; 
 understand the minimal structural requirements to induce immune response; 
 fragments of high purity, that present a suitable linker apt to conjugation with carrier 
proteins. 
In this context however, optimization procedures are required to: 
 simplify and optimize the large scale synthesis of fragments containing challenging structural 
motifs; 
 simplify and optimize the synthesis of fragments made up by several repeating units. 
Thus, a conjugating reagent should possess sufficiently high reactivity in order to: 
 maximize the yield of glycoconjugate; 
 achieve, reproducibly, a proper number of sugars attached to protein; 
 avoid the need for large excess of sugar or protein patterns. 
Moreover, the activated intermediate, precursor of the glycoconjugate, has to tolerate the 
aqueous buffer conditions required in conjugation reaction. 
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FULLY SYNTHETIC GLYCOPEPTIDE VACCINES 
The evolution of this concept deal with fully synthetic glycopeptide vaccines.23 It’s even more 
challenging developing a glycoconjugate by the chemical synthesis of the sugar moiety  together 
with the chemical synthesis of the carrier protein. The carrier is constitute of synthetic peptides 
representing CD4+ T-cell epitopes. MHC class II genetic restriction is the obstacle for human 
application.24   
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The Gram-negative encapsulated organism Neisseria meningitidis is the leading cause of bacterial 
meningitis. This invasive infection affects mostly infants, children, and adolescents who do not 
possess specific antibodies. 
INTRODUCTION 
Meningococcal disease incidence in human population reaches its climax over 100000 
population/year, and it is influenced by the virulence potential of circulating Meningococci by host 
or environmental factors.1 
The first outbreaks of meningococcal meningitis were first described in Geneva in 1804 and in New 
England in 1806, while in 1887 Weichselbaum discovered the causative agent and almost 100 
years ago is dated the beginning of epidemics in the sub-Saharan Africa. 
The family Neisseriaceae consists of Gram-negative aerobic bacteria from fourteen genera, 
including Neisseria, Chromobacterium, Kingella, and Aquaspirillum.  The genus Neisseria contains 
two important human pathogens, N. gonorrhoeae and N. meningitidis. N. gonorrhoeae causes 
gonorrhea, and N. meningitidis is the cause of meningococcal meningitis. N. gonorrhoeae 
infections have a high prevalence and low mortality, whereas N. meningitidis infections have a low 
prevalence and high mortality. 
MENINGITIS 
Bacterial meningitis causes approximately 170,000 annual deaths upon more than 1,200,000 
cases, with at least a 5-10% of case fatality in industrialized countries and a 20% in the developing 
world.2 Meningitis is an inflammation of the protective membranes covering the brain and spinal 
cord, known collectively as the meninges (Figure 1). 
 
Figure 1_Meningitis inflammation. 
The inflammation may be caused by infection with viruses, bacteria, or other microorganisms, and 
less commonly by certain drugs. Meningitis can be life-threatening because of the inflammation's 
proximity to the brain and spinal cord; therefore the condition is classified as a medical 
emergency. 
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The most common symptoms of meningitis are headache and neck stiffness associated with fever, 
confusion or altered consciousness, vomiting, and an inability to tolerate light (photophobia) or 
loud noises (phonophobia). Sometimes, especially in small children, only nonspecific symptoms 
may be present, such as irritability and drowsiness. If a rash is present, it may indicate a particular 
cause of meningitis; for instance, meningitis caused by meningococcal bacteria may be 
accompanied by a characteristic rash. 
In addition,  serious sequelae such as brain damage, hearing loss or a learning disability affect up 
to one third of survivors. Streptococcus pneumoniae, Haemophilus influenzae type b (Hib) and 
Neisseria meningitidis3  are responsible for most of the cases of bacterial meningitis worldwide 
although, with the advent of conjugate vaccines for Hib and for the pneumococcus, the 
meningococcus is the remaining major bacterial pathogen causing meningitis in children and 
adults. 
NEISSERIA MENINGITIDIS 
In 1887 Weichselbaum was the first to isolate the causative agent of cerebrospinal meningitis, 
which he called Diplococcus intracellularis meningitidis. N. meningitidis is an encapsulated, 
diplococci, gram-negative bacterium (Figure 2): its outer membrane is surrounded by a 
polysaccharide coat that is essential for its pathogenicity. 
 
Figure 2_Diplococci encapsulated (green covering) bacterium of N. meningitidis. 
N. meningitidis has been recognized as the cause worldwide of epidemics of meningococcal 
meningitis and meningococcemia.  
N. meningitidis colonizes the upper respiratory tract of almost 10% of human population, and 
humans are the only known host. Individuals who are colonized are carriers of the pathogen who 
can transmit disease to nonimmune individuals. The bacterium is able to enter in the bloodstream, 
where it multiplies to high density and causes a form of sepsis characterized by a dramatic 
disruption of the endothelium and microvasculature. Through the bloodstream the bacterium can 
cross the blood-brain barrier and cause meningitis. 
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In general the meningococcus usually inhabits the human nasopharynx without causing detectable 
disease. This latency may last for a few days to months and is important because it not only 
provides a reservoir for meningococcal infection but also stimulates host immunity. Between 5 
and 30% of normal individuals are carriers at any given time, yet few develop meningococcal 
disease. Carriage rates are highest in older children and young adults. Highest attack rates occur in 
infants from 3 months to 1 year old. Meningococcal meningitis occurs both sporadically (mainly 
groups B and C meningococci) and in epidemics (mainly group A meningococci), with the highest 
incidence during late winter and early spring. The invasive infection affects mostly infants, 
children, and adolescents who do not possess specific antibodies. After infection some of these 
subjects may develop the disease within a few hours and, of them, about 5-15% die while up to 
25% develop permanent damages, such as epilepsy, mental retardation or sensorineural 
deafness.4 
MENINGOCOCCAL SEROGROUPS 
Based on the chemical composition of the polysaccharide capsule, 13 capsular serogroups (A, B, C, 
D, H, I, K, L, X, Y, Z, 29E, and W135) of N. meningitidis have been defined so far, but only six 
serotypes (A, B, C, Y, W135, and recently X) are currently associated with significant pathogenic 
potential.5,6 The relative incidence of N. meningitidis serogroups is strictly dependent on 
geographic area. Serogroups B and C are responsible for the majority of cases of meningococcal 
disease in developed country, i.e. USA and Europe.  
Although all N. meningitidis serotypes can cause epidemics, group A strains (MenA) are the main 
responsible for epidemics in the sub-Saharan Africa (the so-called “meningitis belt”), where the 
annual disease incidence ranges from 1 to 8‰ of the population.7 Most of these infections are 
caused by serogroup A, but since 2002 serogroup W135 has been considered to be also a major 
threat. However, in the past 20 years sporadic cases or clusters of meningitis due to other N. 
meningitidis serogroups have emerged. 
CONJUGATE VACCINES COMMERCIALLY AVAILABLE 
Although there are two licensed vaccines (bivalent A/C and tetravalent A/C/Y/W135) which are 
effective for persons older than two years, the formulation of suitable glycoconjugate vaccines 
against N. meningitidis is required to improve immune responses in young children. Accordingly, 
three monovalent group C conjugate vaccines and a tetravalent meningococcal conjugate vaccine 
against groups A, C, Y and W135 are currently present on the market (Table 1). 
Table 1_Commercially available meningococcal conjugate vaccines. 
N. MENINGITIDIS SEROGROUPS TYPE OF CONJUGATE MANUFACTURER 
A 6)-α-D-ManpNAc(3/4OAc)-(1PO3
- 
C 9)-α-D-Neup5Ac(7/8OAc)-(2 
W135 6)-α-D-Galp (14)-α-D-Neup5Ac(9OAc)-(2 
Y 6)-α-D-Galp (14)-α-D-Neup5Ac(9OAc)-(2 
MenA-TT Serum Institute India 
MenC-CRM197 Pfizer Novartis Vaccines 
MenC-TT Baxter 
MenACWY-DT Sanofi-Pasteur 
MenACWY-CRM197 Novartis Vaccines 
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FULLY SYNTHETIC NEO-GLYCOCONJUGATES 
The groups of Pozsgay8 and Oscarson9 reported the syntheses of fragments (up to the trimer) of 
the MenA CPS, consisting of (1 6)-linked 2-acetamido-2-deoxy- -D-mannopyranosyl phosphate 
residues (Figure 3). 
 
Figure 3_Repeating unit of MenA. 
In particular, Pozsgay described also the conjugation of the synthetic fragments to HSA, showing 
that a polyclonal anti-N. meningitidis A antiserum can recognize a monosaccharide fragment of its 
CPS. However, the MenA CPS suffers from poor stability in water due to the inherent lability of the 
anomeric phosphodiester groups bridging two N-acetyl mannosamine units. This structural 
property makes the development of a fully synthetic glycoconjugate vaccine a challenging task. 
The access to synthetic analogues endowed with both the immunological properties of the natural 
compounds (i.e., the ability to induce the production of antibodies that will cross-react with the 
bacterial capsule) and an increased stability in water, is therefore highly desirable. For this 
purpose, syntheses of phosphonoester-bridged fragments of the MenA CPS, where 1-C-
phosphonates have been used as isosteric and nonhydrolyzable analogues of glycosyl 1-O-
phosphates, have been reported by Oscarson10 and our group11. We also investigated the relative 
affinities of the synthetic molecules (monomer, dimer and trimer, Figure 4) by using a competitive 
ELISA assay (Enzyme-Linked ImmunoSorbent Assay), showing that the synthetic fragments 
containing the unnatural interglycosidic phosphonoester linkage are recognized by a human 
polyclonal anti-MenA serum.10b 
 
Figure 4_ Phosphonoester-linked oligomers of Neisseria meningitidis A capsular polysaccharide. 
Following these encouraging results, the synthetic oligomers were conjugated to passivating thiols 
and employed for the fabrication of multivalent gold glyconanoparticles mimicking the bacterial 
capsule.12 Interestingly, gold glyconanoparticles displaying the synthetic Men A CPS fragments 
bind to specific anti-MenA antibody with at least two orders of magnitude higher than the 
corresponding non-conjugated, monovalent oligomers.13 Investigations are in progress to establish 
whether these gold glyconanoparticles are also able to induce immune cell responses.  
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N. MENINGITIDIS TYPE X 
In 1963 Slaterus14 isolated new types of Meningococci from patients in a non-epidemic period in 
Netherlands. The new types were X, Y, and Z: these three strains failed to react with antisera 
prepared against A, B, C, and D strains15, first discovered by Branham. In 1973, Bundle, Kenny, and 
Jennings have improved the procedure for MenX isolation.16 
MENX STRUCTURE 
The structure of N. meningitidis type X (MenX) was first elucidated by Bundle and co-workers in 
1974.17 The Men X polysaccharide antigens consists of linear chains of 2-acetamido-2-deoxy-D-
glucopyranose linked (14)-α by phosphodiester bonds.18 That MenX polysaccharide was an 
homopolymer of 2-acetamido-2-deoxy-glucosyl phosphate was demonstrated by analytical data, 
shown in Table 2.  
Table 2_Analysis of MenX polysaccharide. 
Composition % by weight
a 
Molar ratio 
Carbon 29.2  
Hydrogen 4.3  
Nitrogen 4.3  
Phosphorous 9.3 1.0 
Total acetyl 12.7 0.98 
O-Acetyl 0.0  
Glucosamine 51.8 0.97 
Amino acids
b 
<1  
Nucleic acids
c 
~2-3  
a corrected for moisture 
b
 determined by Lowry’s method
19
 and Technicon AutoAnalyzer 
c determined by ultraviolet absorption (260 and 280 nm) 
Glucosamine, N-Acetyl, and phosphate are present in equimolar proportions in the polymer. 
Moreover, MenX homopolymer has an average chain length of 50 units, differently from its 
cognate N. meningiditis A CPS, it does not contain O-acetyl groups in the backbone. 
REPORTED MENX CASES  
MenX was responsible of rare cases of meningococcal diseases, meningitis in particular,  in North 
America,20 Europe,21 Australia,22 Africa23 and the People’s Republic of China.24 More recently, 
MenX has emerged in Africa as pathogenic potential: it has caused increasing cases of meningitis. 
Men X outbreaks have been described in Ghana5d (9 cases over a 2-year period) and in Niger (134 
cases between 1995 and 2000,25 representing almost 4% of the meningococcal isolates from all 
cerebrospinal fluid samples). 
It was in 2006, however, that WHO started to consider Men X as a substantial threat, when an 
unprecedented incidence of meningitis caused by Men X was observed in Niger: 51% of 1,139 
confirmed cases of meningococcal meningitis were found to be caused by serogroup X.26 In the 
same year, a meningococcal disease outbreak was notified in Western Kenya, bordering Uganda, 
with 74 cases reported between January and March and 27% ascribed to Men X infections.27 
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The meningitis cases due to Men X do not present any clinical or epidemiological difference from 
those due to serogroup A. Most cases (93%) were recorded during the dry season, with a mean 
age of the patients of 9.2 years and a fatality rate of 11.9%.28 
Very recently, a case of invasive meningococcal disease caused by MenX was described in Italy: the 
patient was a 55-year-old Italian woman.29  
MENX VACCINE 
As mentioned above, serogroups A, B, C, Y and W135 are responsible for most meningococcal 
disease worldwide. However, recent outbreaks of Men X indicate that this serogroup also has 
considerable pathogenic potential. Vaccines currently available on the market against 
meningococcal disease, as well as those under licence, do not include antigenic components of 
Men X, and therefore they do not offer protection against infections caused by this emerging 
serogroup. Although serogroup X usually causes only a small proportion of meningococcal disease, 
it is possible that repeated vaccination against some serogroups (especially A and C) in many 
African countries has the potential to select meningococci of other serogroups (for example, Men 
X) and might result in a changed profile of meningococcal disease. This possibility should be 
considered when conjugate vaccines carrying limited ranges of serogroups are introduced.30 The 
development of more comprehensive conjugate vaccines including Men X CPS fragments could 
therefore become an urgent issue in the near future.  
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INTRODUCTION 
The linkage of a glycosyl phosphate unit with an hydroxyl group of another saccharide  acceptor 
provides a glycosyl phosphodiester. The cell wall, or capsule, of many bacteria and yeasts, as well 
as the extracellular surface of protozoan parasites, are composed by phosphoglycans with this 
type of linkage. It could be also found in animals glycoproteins. It is well known that the antigenic 
determinants, which define the immunogenical specificity, are in many case constituted by 
glycosyl phosphate units. 
Natural phosphoglycans composed of glycosyl phosphate (or oligoglycosyl phosphate) repeating 
units could be chemically classified as poly(glycosyl phosphates). Since phosphoglycans are 
immunologically active components of the outer membrane of pathogenic microbes, it is 
important to develop a synthetic route for chemical preparation of fully synthetic biopolymers. 
The synthesis of anomeric phosphodiesters is a challenging task (Scheme 1), due to the 
stereochemical configuration of the hydroxyl group in anomeric position together with the lability 
of anomeric phosphodiester O-linkages. 
 
Scheme 1_The stereochemical control in phosphodiester bridge synthesis. 
In literature, there are three review papers describing the chemical preparation of fully synthetic 
glycosyl   phosphodiester-linked oligomers: by Thiem and Franzkowiak in 1989,1 by Hansson and 
Oscarson in 2000,2 and by Nikolaev et al. in 2007.3 
CHEMICAL SYNTHESIS OF GLYCOSYL PHOSPHOSACCHARIDES 
To date, there are examples of synthetic fragments containing the 1- phosphates of: 
 α-D-mannopyranose,  α-D-glucopyranose,  α-D-galactopyranose, α-L-fucopyranose,  α-D-
rhamnopyranose, α-L-rhamnopyranose; 
 2-acetamido-2-deoxy-α-D-mannopyranose,  2-acetamido-2-deoxy-α-D-glucopyranose,  2-
acetamido-2-deoxy-α-D-galactopyranose. 
As far as the preparation of glycosyl phosphosaccharides is concerned, five basic synthetic 
methodologies can be found in literature: 
i. Phosphodiester; 
ii. Phosphotriester; 
iii. Phosphorous (or Phosphite) triester [including phosphoramidite and phosphorochloridite 
versions]; 
iv. Hydrogen-phosphonate (H-phosphonate) approaches; 
v. Others based on the glycosylation reaction. 
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Scheme 2_Approaches to glycosyl phosphosaccharides synthesis. 
The first four methods were originally designed for nucleotide chemistry: their mechanism is 
based on the condensation of various P-containing glycosyl components (electrophiles) with 
alcohol monosaccharide derivates (nucleophiles). 
For 20 years the chemical synthesis of glycosyl phosphosaccharides was based on phosphodiester 
approach, developed in the mid-1950s.4 The phosphotriester5 and the H-phosphonate6 methods 
were pioneered by Todd’s group during 1950’s, and optimized7,8 later. In 1981 the 
phosphoramidite method9 was discovered and after that, thanks to its simplicity and efficiency, it 
became the most used. 
P(V) CHEMISTRY: PHOSPHODIESTER AND PHOSPHOTRIESTER METHODS 
PHOSPHODIESTER METHOD 
In 1971, Cawley and Letters published the first chemical synthesis of mannosyl phosphodiesters 
(14)- and (16)-linked.10 
The phosphodiester method is historically the first method used, moreover it is conceptually the 
simplest: a protected glycosyl phosphate is coupled with an hydroxyl carbohydrate acceptor (i.e. 
Scheme 3) by condensing reagents.  
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Scheme 3_Phosphodiester approach. 
The most used condensing reagents are dicyclohexylcarbodiimide (DCC), 2,4,6-
triisopropylbenzenesulfonyl chloride (TPS-Cl) or 3-nitro-1-(2,4,6-triisopropylbenzenesulfonyl)-
1,2,4-triazole (TPS-NT). The glycosyl phosphate is synthesized by glycosylation reactions (see 
below) or by simple manipulations of commercially available glycosyl phosphates. 
In 1978 the first application on N-acetyl-D-glucosamine substrate is showed.11 In general, the most 
compounds synthesized with the present method contained mostly the (16)-linked 
phosphodiester linkages. Concerning the condensation/deprotection steps of α-D-Glcp 1-
phosphate compounds, the yields are moderate and ranged from 69% to 15%, while in the case of 
α-D-GlcpNAc 1-phosphate derivatives the yields are constantly very low (<20%). The rate of 
coupling reaction is influenced by the condensing reagent used: reactions proceeded in 2-10 days 
using DCC or TPS-Cl, while the use of TPS-NT allowed to decrease the reaction time to 7 hours. 
PHOSPHOTRIESTER METHOD 
The Phosphotriester approach is a variant of the previous method. In this case the glycosyl 
phosphate is P-protected (see Scheme 4). 
 
Scheme 4 
The phosphotriester method is suitable for nucleotide chemistry, moreover the yields resulted in 
increases by the use of solid-phase synthesis of oligodeoxyribonucleotides.12 By contrast, this 
method is not efficient for the synthesis of glycosyl phosphosaccharides. 
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P(III) CHEMISTRY: PHOSPHOROUS TRIESTER AND H-PHOSPHONATE 
METHODS 
PHOSPHOROUS TRIESTER (PHOSPHITE TRIESTER) METHODS 
PHOSPHOROCHLORIDITE METHOD 
Ogawa and Seta13 have first pioneered the use of P(III) compounds. The 2,2,2-trichloroethyl 
phosphorodichloride (Scheme 5) is used to phosphitylate the hemiacetal and form the glycosyl 
phosphorochloridite, which then is coupled to provide a phosphorous triester (generally in high 
yields): the desired phosphosaccharide is obtained after a step of oxidation followed by P-
deprotection (Zn-Cu couple in the presence of 2,4-pentadione). 
 
Scheme 5_Phosphorochloridite approach. 
PHOSPHORAMIDITE METHOD 
The van Boom’s group developed the phosphoramidite method (Scheme 6).14 The glycosyl 
phosphoramidite is achieved by the use of N,N-di-isopropylphosphoramidochloridite, and 
successively coupled with a suitable alcohol acceptor to give the phosphoroustriester. Again, a 
step of oxidation followed by P-deprotection (NH3) provides the desired phosphodiester. The 
completion of the reaction has to be monitored by 31P-NMR, and sometimes the ammonolysis of 
the cyanoethyl group is accompanied by partial cleavage of the glycosyl phosphate linkage. 
The best reaction procedure has been optimized by Kajihara and co-workers.15 
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Scheme 6_Phosphoramidite approach. 
The application of this method to N-acetyl-D-glucosamine is not without problems: the moderate 
yields are explained with the formation of oxazoline and monosaccharide phosphate by-products 
by 2-acetamido group participation (Scheme 7). 
 
Scheme 7_Oxazoline and monosaccharide phosphate by-products. 
HYDROGEN-PHOSPHONATE METHODS 
In the mid-1980s the first applications of H-phosphonate method in carbohydrate chemistry were 
described by van Boom’s group16,17 and by Nikolaev’s group18. 
A glycosyl H-phosphonate sugar-type B is coupled with an alcohol derivative C in the presence of a 
condensing reagent17,19,20 to produce a H-phosphonate diester D, which forms the target E by in 
situ oxidation (Scheme 4). The most used condensing reagent is trimethylacetyl chloride17 (Pivaloyl 
chloride, PivCl) and the oxidation step is normally performed in situ using iodine in aqueous 
pyridine. 
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Scheme 8_H-phosphonate approach: starting materials and intermediates. 
The glycosyl H-phosphonate B can be obtained from the corresponding α-hemiacetal A or the α,β-
hemiacetal F. 
The H-phosphonate derived from A (pure α sugar) can be achieved using either 
 tri-imidazolylphosphine (generated in from PCl3, imidazole and Et3N)
8b,19,20,21 
 2-chloro-1,3,2-benzodioxaphosphorin-4-one (commonly named salicylchlorophosphite)16,17 
or  
 diphenyl phosphite22,23  
for phosphonylation followed by hydrolysis. 
The reaction of α,β-hemiacetals F with salicylchlorophosphite in pyridine24 or H3PO3 in the 
presence of 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinane25,26 leads to the formation of 
the pure α-glycosyl H-phosphonate B. 
By 31P-NMR studies Nikolaev27 and co-workers demonstrated that: 
 during the coupling between H-phosphonate B and alcohol C the mixed anhydride H 
(Scheme 4) is the main reactive intermediate leading to the formation of H-phosphonate 
diester D: this is further oxidised to phosphodiester E; 
 prolonged delay (more than 24 hours) of the oxidation step can lead to decomposition of the 
substrates thus resulting in low yield of E by partial transformation of D into C-phosphonate 
and phosphorous triester derivatives; 
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 the solvent can participate in the reaction as a nucleophilic catalyst to assist the 
transformation of H and D via activated pyridinium intermediate I (in according to data 
describing the behaviour of H-phosphonates in pyridine). 
In contrast to both the phosphodiester and the phosphoramidite, H-phosphonate is the most 
efficient method for general preparation of glycosyl phosphosaccharides and in particular of 
glycosyl phosphodiester containing N-acetyl-α-D-glucosamine units. The most prominent 
characteristics of this method are: 
 high effectiveness; 
 high reaction rate for all the three steps involved; 
 does not require a P-protecting group; 
 high yields. 
THE GLYCOSYLATION REACTION 
The glycosylation reaction method is exclusive for carbohydrates. This approach, exemplified in 
Scheme 9, involves the reaction of a glycosyl donor (electrophile) with a P-containing glycosyl 
acceptor (nucleophile). 
 
Scheme 9_Glycosylation reaction approach. 
The substitution of a suitable leaving group at the anomeric position with a phosphoric acid 
derivative provides the phosphodiester linkage. The glycosyl trichloroacetimidates are the most 
used glycosyl donors.28 The yields ranged from moderate to good and the stereochemical control 
of the reaction depends mainly on three factors: the stereochemistry of the glycosyl donor, the 
nature of the protecting groups of the patterns, and the reaction conditions. 
Some examples of combination between the glycosylation and the H-phosphonate methods are 
reported in literature.29 
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RESEARCH METHODOLOGY 
The aim of the present research project is the synthesis of phosphodiester-linked oligomers of the 
native Men X CPS (Figure 1). 
 
Figure 1_Synthetic MenX oligomers. 
The synthetic plan is based on the Hydrogen-phosphonate approach (H-phosphonate).1 The choice 
of Hydrogen-phosphonate (H-phosphonate) approach for the synthesis of phosphodiester-linked 
oligomers was due to the advantages of this method compared to the others (see CHAPTER 4). 
Moreover, each oligomer contains a phosphodiester-linked aminopropyl spacer at its reducing end 
to allow protein conjugation and synthesis of neo-glycoconjugates capable to elicit a stronger and 
durable immune response (Figure 2). 
 
Figure 2_Men X neo-glycoconjugates. 
The synthetic compounds have been first conjugated to HSA as a proof of principle, then to the 
more immunogenic carrier protein CRM197.
2 
PROTECTING GROUP STRATEGY 
The first part of the synthetic endeavour has been devoted to the preparation of suitably 
protected monosaccharide building blocks (Scheme 1), as key precursors of our synthetic route. 
 
 
Scheme 1_Suitably protected monosaccharides: the key precursors of the synthetic route. 
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Protecting group strategy was crucial for a successful outcome of the project. Then, permanent 
protecting groups (PG2) should be introduced on 3-OH and 6-OH, while temporary protecting 
groups (R1 and R2) should be selected in order to allow selective unblocking of the corresponding 
hydroxyls and to allow elongation of the oligomers. In addition, an azide (PG1) was installed on C-2 
in agreement with literature data, where nearly all syntheses of similar compounds relied on the 
2-azido group as a non-participating precursor of the 2-acetamido moiety. 
The stereochemical control in the synthesis of α-phosphodiester-linked oligomers was the first 
goal of the present work. The proposed synthetic strategy is illustrated in Scheme 2. 
 
Scheme 2_The proposed synthetic strategy. 
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Starting from commercially available D-glucosamine hydrochloride, we were able to achieve a 
suitably protected key precursor of our route: its structure and synthesis is described in the next 
paragraph. The selective delivery either of the anomeric position or of 4-OH enabled the blockwise 
elongation. The unblocking of R1 allowed to obtain an hemiacetal intermediate apt to be coupled 
via H-phosphonate with the 3-N-carbobenzyloxy aminopropyl spacer. The obtained monomer, 
after delivery of 4-OH, was the glycosyl acceptor to provide the dimer following the same 
approach with a second residue of hemiacetal intermediate. The iteration of the above protocol 
led to oligomers of different length. 
SYNTHETIC STRATEGY 
The first part of the synthetic endeavour has been devoted to the preparation of the suitably 
protected monosaccharides 1 and 2 (Scheme 3), in medium (up to 2 g) and large scale (5-30 g) 
synthesis. 
 
Scheme 3_Key precursors 1 and 2. 
Why a second key precursor? 
We reasoned that oligomer elongation based on 2 was a much reliable approach, since O-
deacetylation is a milder and safer transformation in comparison with regioselective/reductive 
opening of benzylidene acetal. The latter required indeed strongly acidic conditions, which could 
lead to partial decomposition of longer oligomers. On the other hand, we envisaged 1 as a capping 
sugar (the non-reducing end) for the completion of the targets (Scheme 4). 
 
Scheme 4_The synthetic strategy for oligomer elongation. 
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SYNTHESIS OF KEY PRECURSORS 1 AND 2 
Medium scale synthesis (up to 2g) 
In principle, fully protected building block 1 can be synthesized just in 4 steps (37% overall yield). 
This route was however not reproducible when using large amounts of starting material. 
Starting from the commercially available D-glucosamine (Scheme 5), the amino group was masked 
as an azide (3) by using the diazo-transfer reaction.3 Without any further purification, the 
introduction of a 4,6-O-benzylidene acetal4 (4) and the selective silylation of 1-OH with 
thexyldimethylsilylchloride5 (TDSCl) led to compound 5 in 65% yield over three steps. The last free 
hydroxyl group was then protected as a benzyl ether6 to achieve the key precursor 1 in 72% yield. 
 
Scheme 5_Synthesis of key precursor 1 and hemiacetal 6. 
Building block 2 was obtained from 1 by regioselective reductive opening of the benzylidene 
acetal7 (7, 89% yield) followed by acetylation at 4-OH (96% yield, Scheme 6). 
Hemiacetals 6 (Scheme 5) and 8 (Scheme 6) were synthesized by desilylation of the corresponding 
building blocks using tetrabutylammonium fluoride (TBAF) 1M in THF and glacial acetic acid (80% 
and 94% yield, respectively).19 
During the preparation of 5 (2-5 g), the overall yield was very low and we observed the formation 
of the bis-silylated by-product. Since the silylation was performed on crude diol 4 (derived in turn 
from crude 3), we used a very large excess of TDSCl causing a substantial bis-silylation. 
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Scheme 6_Synthesis of key precursor 2 and hemiacetal 8. 
Moreover, the use of trifluoromethanesulfonyl azide (TfN3, Scheme 4) as a “diazo donor” in the 
Cu(II)-catalyzed conversion of the amine into the azide led to high yields. However, this process 
included several drawbacks: 
 the explosive nature of neat TfN3 and its relatively poor shelf life; 
 the high cost of Tf2O; 
 the removal of trifluoromethanesulfonamide from polar products required specialized work-
up procedures; 
 the laborious work-up procedure, particularly challenging in large-scale (> 10 g) 
preparations. 
To circumvent these problems and establish the diazotransfer reaction as a commonplace and 
industrially useful synthetic transformation, a cheap, robust, and safe alternative to TfN3 was 
required. In particular, we needed an electron-withdrawing group capable of replacing the 
trifluoromethanesulfonyl moiety, and we chose the imidazole-1-sulfonate (imidazylate)8, which is 
known to exhibit very similar reactivity to trifluoromethanesulfonates but benefits by a longer 
shelf life: accordingly, imidazole-1-sulfonate hydrochloride 9 (77% yield) was employed for the 
preparation of azide 3 (quantitative yield) as described in the literature (Scheme 7).20 
 
Scheme 7_Synthesis of imidazole-1-sulfonate hydrochloride 9 and glucopyranosyl azide 3. 
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Large scale synthesis 
In large scale synthesis (5-30 g), we applied a longer but more reliable approach for the synthesis 
of 1 (23% yield over 6 steps, Scheme 8): in this way we could achieve intermediate 1 in higher 
purity and yield. 
 
Scheme 8_Large scale synthesis of building block 1. 
The diazotransfer reaction was followed by acetylation that enables the purification of 10 by flash 
chromatography. Although this reaction is described in the literature9 in 94% yield, we got 77% 
yield as the best result. The next step consisted in the regioselective removal of the anomeric 
acetate by a freshly prepared 2M solution of hydrazine acetate in DMF: hemiacetal 11 was 
obtained in very high yield (90%). The silylation of the anomeric position with TDSCl (12, 73% yield) 
followed by Zemplen deacetylation10 (13, quantitative yield) allowed the introduction of a 4,6-O-
benzylidene acetal to get alcohol 5 (63% yield), that was eventually transformed into building 
blocks 1 by standard benzylation protocol. 
APPROACHES TO THE CONSTRUCTION OF OLIGOMERS 
As far as the elongation of our oligomers is concerned (Scheme 9), we decided to install the 
phosphodiester linkages via the well-established H-phosphonate approach. In principle, there are 
two main approaches towards this task: 
A - the coupling between an hemiacetal derivative and a stable non-anomeric H-phosphonate 
(4-H-phosphonate-glucoside or linker H-phosphonate); 
B -  the coupling between an anomerically pure α H-phosphonate and an acceptor (saccharide 
or spacer). 
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Scheme 9_Phosphodiester bridge formation: approach A and approach B. 
The stereochemical control in the synthesis of phosphodiester-linked oligomers is a challenging 
task. First, we applied approach A based on the oxidative coupling between hemiacetal 6 and 3-N-
carbobenzyloxy-propanolamine H-phosphonate 14 (Scheme 10). 
 
Scheme 10_Synthesis of 15: first attempt of coupling. 
Compound 14 was obtained by the treatment of 3-N-carbobenzyloxy-aminopropanol with 
salicylchlorophosphite in acetonitrile/pyridine mixture and then with 1M triethylammonium 
bicarbonate (TEAB) buffer leading to the formation of 14 (60% yield) in 2 hours (Scheme 11). In a 
scale of 2g the yield decreased because of the formation of by-product 16. 
 
Scheme 11_Small scale synthesis of H-phosphonate 14. 
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For large amount preparation, we changed the procedure using phosphorous acid (H3PO3) instead 
of salicylchlorophosphite as phosphilating agent (Scheme 12). 
 
Scheme 12_Large scale synthesis of H-phosphonate 14. 
Next, compound 6 and H-phosphonate 14 were coupled under standard conditions (see the 
Experimental section, CHAPTER 8), and the resulting H-phosphonate diester was in situ oxidized 
with iodine in a pyridine/water mixture to provide the phosphodiester 15. However, NMR analysis 
evidenced the predominant formation of the β anomer of 15. Likewise, the synthesis of a 
phosphodiester-linked disaccharide according to approach A led to an inseparable mixture of 
anomers, suggesting that a different approach (approach B) must be employed to achieve our 
goal. 
The application of approach B requires the obtainment of an anomerically pure α H-phosphonate 
intermediate. Since there are no examples in literature describing the synthesis of exclusively α-
anomeric H-phosphonate from 2-azido-2-deoxy-glucopyranosyl derivatives, we decided to focus 
our attention on the synthesis of 17 by introducing the H-phosphonate moiety on 6 (Scheme 13). 
 
Scheme 13_Synthesis of α-pure H-phosphonate 17, following the approach B. 
The leading concept is to achieve equilibration of the initially formed α,β mixture of the anomeric 
H-phosphonates into the pure, more thermodynamically stable α anomer 17. 
To this aim, we explored different protocols (Table 1): 
I. treatment of 6 with a slight excess of salicylchlorophosphite in a mixture of dry dioxane and 
pyridine at r.t.; 
II. treatment of 6 with salicylchlorophosphite in a mixture of dry acetonitrile and pyridine, from 
0°C to r.t.;11 
III. treatment of 6 with triimidazolylphosphine (prepared in situ from PCl3, imidazole and 
triethylamine) in dry acetonitrile, from 0°C to r.t.;12 
IV. treatment of 6 with H3PO3 and 2-chloro-5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorinane in 
pyridine, from r.t. to 40°C;14 
V. treatment of 6 with H3PO3 and salicylchlorophosphite in pyridine, from r.t. to 40°C. 
In all cases, the reaction course was monitored by NMR analysis (1H and 31P). 
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Method V is our modification of method IV (described in the literature14) that gave the best results 
(Table 1, entries 6 and 7).  
Table 1_Different reaction conditions explored.. 
entry 
amount of 6 
(1eq) 
phosphitylating agent acid solvent 
temperature 
(°C) 
α:β ratio 
1 55 mg 
salicylchlorophosphite 
(1.2 eq) 
- 
dioxane/pyridine 
3:1 
0.3 M 
r.t. 2:1 
2 47 mg 
salicylchlorophosphite 
(1.2 eq) 
- 
dioxane/pyridine 
3:1 
0.3 M 
0°C to r.t. 2:1 
3 53 mg 
PCl3 (5 eq) 
 imidazole (5.5 eq) 
triethylamine (5.7 eq) 
- 
acetonitrile/pyridine 
5:3 
0.3 M 
0°C to r.t. 3:1 
4 88 mg 
2-chloro-5,5-dimethyl-
2-oxo-1,3,2-
dioxaphosphorinane 
(5 eq) 
H3PO3  
(10 eq) 
acetonitrile 
0.3 M 
r.t. to + 40°C - 
5 200 mg 
salicylchlorophosphite 
(5 eq) 
H3PO3  
(10 eq) 
pyridine 
0.4 M 
r.t. to + 40°C 4:1 
6 48 mg - 1 g 
salicylchlorophosphite 
(5 eq) 
H3PO3  
(4 eq) 
pyridine 
0.4 M 
r.t. to + 40°C > 95:5 
7 50 mg - 2 g 
salicylchlorophosphite 
(1.5 eq) 
H3PO3  
(3 eq) 
pyridine 
0.4 M 
r.t. to + 40°C > 95:5 
After disappearance of the starting material 6, a 1:1 α,β ratio was determined by 1H- and 31P-NMR 
of the crude sample (Figure 3). After 6 days at r.t., the ratio moved to 2:1. As the reaction 
temperature was raised up to 40°C, the α,β ratio increased progressively, from 7:1 (after 12 hours 
at 40°C) until 98:2 (after further 3 days at 40°C, 48% yield). 
 
Figure 3_Synthesis of 17: 
1
H- and 
31
P-NMR spectra of reaction’s aliquots. 
H-phosphonate 18 was also synthesized following procedure V (52% yield, Scheme 14). Unlike the 
case of 6, we decided to increase the temperature up to 40°C as soon as the disappearance of the 
starting material 8 occurred (1.5 hour). 
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Scheme 14_Synthesis of α-pure H-phosphonate 18. 
After 1 day the 2:1 α,β ratio was determined by 1H- and 31P-NMR of the crude sample (Figure 4). 
After 3 days at 40°C the ratio moved to 7:1, and it increased progressively until 98:2 (after 2 days 
more at 40°C). 
 
Figure 4_Synthesis of 18: 
1
H- and 
31
P-NMR spectra of reaction’s aliquots. 
We also tried to reduce the reaction time by treatment of 8 with a slight excess of 
salicylchlorophosphite (1.2 eq) in a 1:1 mixture of dry dioxane and triethylamine at r.t. (20% yield). 
Disappointingly we observed the formation of unknown by-products in 31P-NMR and the α,β ratio 
was 2:1. 
After several attempts, some considerations can be assumed: 
 in comparison with 17, the reaction time needed for the synthesis of 18 is much shorter (10 
days vs. 6 days, respectively), due to the higher reactivity of the starting hemiacetal; 
 further addictions of reagents (H3PO3 and/or salicylchlorophosphite) leads to decomposition 
and it’s not helpful to the reaction’s progress; 
 in large scale synthesis (up to 2 g), extended reaction times were noticed; 
 in both cases, yields were moderated. 
To explain the last issue, a reasonable mechanism of the H-phosphonate formation is displayed in 
Scheme 15.  
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Scheme 15_Mechanism of H-phosphonate formation. 
The H3PO3 is responsible for the decomposition of the β adduct pyridinium salt, leading to the 
recovery of the starting material. 
In agreement with this mechanism, we observed the formation of substantial amounts of 
hydrolysis by-product (starting material) by 1H-NMR (Figure 5), which however can be easily 
recycled. 
α/H1 = 1:0
α/H1 = 2:1
α/H1 = 3:2
α/H1 = 1:1
α/H1 = 1:0.1
α/H1 = 1:0.2
α/H1 = 3:2
α/H1 = 1:1
 
Figure 5_
1
H-NMR spectra of H-phosphonates, 17 and 18, reaction crudes: the by-product formation is highlighted in yellow. 
Starting from α-H-phosphonate 17, the synthesis of the spacer-containing monomer was achieved 
in 3 steps (Scheme 16): 
 coupling between 17 and 3-N-carbobenzyloxy-propanolamine to give 15 (62% yield); 
 NH-acetamide 19 formation by azide reduction (low yield, see below); 
 Pd/C catalyzed hydrogenation followed by ion exchange to achieve 20 in quantitative yield. 
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Scheme 16_Synthesis of monomer 20. 
Disappointingly, the classical Staudinger reduction13 of azide 15 did not work in our hands 
(Scheme 17). The iminophosphorane 21 (the typical Staudinger intermediate) exhibited 
unexpected stability towards water hydrolysis, even at high temperature (80°C). 
 
Scheme 17_Azide reduction: the Staudinger reaction. 
NH-acetamide 19 was therefore achieved by “NiCl2/NaBH4” protocol followed by in situ 
acetylation (13% yield). 
The coupling between H-phosphonate 18 and the linker was accomplished in standard conditions 
(Scheme 18). 
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Scheme 18_Synthesis of alcohol acceptor 23. 
The 3-N-carbobenzyloxy-propanolamine was the limitating agent, while 18 and PivCl were used in 
excess. 
Oligomers elongation was achieved by O-deacetylation (23, quantitative yield)  of monomer 22 
followed by the coupling with H-phosphonate 17, obtaining smoothly dimer 24 (Scheme 19), even 
if in low yield. 
 
Scheme 19_Synthesis of dimer 24: the coupling between acceptor 23 and H-phosphonate 17. 
Alcohol 23 is the precursor for the synthesis of both the dimer and the trimer. In order to confirm 
our previous assumption (i.e. the benzylidene acetal is not the optimal protecting group for 
blockwise oligomer chain elongation), we tried the regioselective/reductive opening of 
benzylidene 15 (Scheme 20), obtaining the decomposition of the product. 
 
Scheme 20_Regioselective reducting opening of benzylidene acetal 15. 
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NH-acetamide 25 was obtained by “NiCl2/NaBH4” protocol followed by in situ acetylation, then 
Pd/C catalyzed hydrogenation followed by ion exchange led to dimer 26 in quantitative yield 
(Scheme 21). 
 
Scheme 3_Synthesis of dimer 26. 
Trimer formation needed 2 steps more, following the same strategy. Coupling between H-
phosphonate 18 and alcohol 23, followed by oxidation, provided dimer 27 (20% yield, Scheme 22). 
 
Scheme 4_Synthesis of dimer 27: the coupling between acceptor 23 and H-phosphonate 18. 
Oligomer elongation was achieved by O-deacetylation of dimer 27 (28, quantitative yield), and 
reaction of 17 with 28 to get the phosphotrisaccharide 29 (43% yield, Scheme 23). 
NH-acetamide 30 was obtained by “NiCl2/NaBH4” protocol followed by in situ acetylation (25% 
yield), then Pd/C catalyzed hydrogenation and ion exchange furnished trimer 31 (quantitative 
yield). 
“Synthesis and conjugation of Neisseria Meningitidis X Capsular Polysaccharide Fragments“ 
Synthetic MenX CPS fragments 
 
 
C
H
A
P
TE
R
 5
: S
YN
TH
ET
IC
 S
TR
A
TE
G
Y 
61 
 
 
Scheme 5_Synthesis of trimer 31. 
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SYNTHESIS OF NEO-GLYCOCONJUGATES 
NEO-GLYCOCONJUGATES FOR BIOLOGICAL ASSAYS 
Further goal of the present thesis was the synthesis of neo-glycoconjugates based on fully-
synthetic MenX fragments. The glycoconjugates will be employed for mice immunization and 
ELISA (Enzyme-Linked ImmunoSorbent Assay) assay at Novartis Vaccines and Diagnostics Research 
Centre in Siena. 
To this aim, two different immunogenic proteins were employed: CRM197
1
 (Cross-Reacting 
Material 197, a non-toxic mutant of diphtheria toxin) was used for immunizations, while Human 
Serum Albumin (HSA) for ELISA tests. With conjugate vaccines, the first carrier proteins were 
diphtheria and tetanus toxoids, that require detoxification. CRM197, first isolated in 1973, does not 
need chemical detoxification and maintains its native three-dimensional structure during 
processing. Lysine residues in CRM197 presented outwardly on the molecule can link with 
polysaccharides through a suitable linker molecule (i.e. adipic acid). 
CRM197 is commonly used as carrier protein in carbohydrate based conjugate vaccines, especially 
in routine childhood vaccines.2 Concerning meningococcal diseases, Menveo® (Novartis Vaccines, 
Switzerland) is a tetravalent meningococcal CRM197-conjugate vaccine against meningococcal 
serogroups A, C, W-135, and Y that has been licensed for use.3 
Moreover two chemically different spacers were used as molecular bridges, namely an adipate  for 
CRM197 and a PEG-based spacer for HSA. In particular, ELISA test is performed to determine the 
antibody specificity.  
This study was designed to better understand immunogenical profile of synthetic antigens, and to 
investigate whether synthetic MenX glycoconjugates can compete with neo-glycoconjugates 
obtained with purified CPS. 
CONJUGATION OF FRAGMENTS TO CARRIER PROTEINS 
During  my stage as a visiting scientist in Novartis, the neo-glycoconjugates based on  monomer 
and dimer fragments were synthesized. 
Disuccinimidyl adipate was used to activate synthetic fragments apt to conjugation with CRM197 
(Scheme 1). After purification (see the Experimental section, CHAPTER 8), activated 
oligosaccharides 32 and 34 were then reacted with CRM197 (stoichiometry 100:1 
molsugar/molprotein). 
On the other hand BS(PEG)5 (bis-succinimidyl penta-ethylene glycol) was used as immunosilent 
spacer apt to conjugation with HSA (stoichiometry 100:1 molsugar/molprotein, Scheme 2).  
CRM197 and HSA glycoconjugates were analysed by SDS-PAGE (Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis)4 and MALDI-TOF analysis.  
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Scheme 1_Synthesis of monomer-CRM197 glycoconjugate 33 and dimer-CRM197 glycoconjugate 35. 
 
Scheme 2_Synthesis of monomer-HSA glycoconjugate 37 and dimer-HSA glycoconjugate 39. 
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A fundamental parameter in the synthesis of neo-glycoconjugates is the loading on the carrier 
protein. The sugar/protein ratio was determined by MALDI spectra, while the SDS-PAGE allowed 
to confirm the occurrence of the conjugation. The profiles of the glycoconjugates were composed 
of polydispersions: 
 MG(CRM197) 33 was 62258.89 m/z, corresponding to approximately 7 sugar chains per 
protein molecule; 
 DG(CRM197) 35 was 61731.51 m/z, corresponding to approximately 4 sugar chains per 
protein molecule; 
 MG(HSA) 37 was 68320.268 m/z, corresponding to approximately 3 sugar chains per 
protein molecule; 
 MG(HSA) 39 was 67734.440 m/z, corresponding to approximately 1 sugar chain per protein 
molecule. 
First attempts of glycoconjugations were not successful, but new attempts are currently in 
progress. 
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SYNTHESIS OF THE TETRAMER 
CONSIDERATIONS ABOUT THE SYNTHETIC STRATEGY 
A significant drawback in the synthesis of  monomer 20, dimer 26, and trimer 31 from H-
phosphonates 17 and 18 was the low yield of some crucial steps. In particular: 
 the condensation of the H-phosphonate with the proper alcohol acceptor (in contrast with 
the good results reported in literature); 
 the azide reduction. 
Concerning the coupling, we also explored the inverse procedure. Briefly, the donor was co-
evaporated 3 times with dry pyridine and/or dry toluene and let it dry in vacuum pump overnight, 
then it was dissolved in pyridine and pivaloyl chloride was added: after 15 minutes a solution of 
the acceptor in dry pyridine was added. However this procedure did not lead to a significant 
improvement of the chemical yields. Likewise, the use of the H-phosphonate (instead of the 
alcohol) as a limitating agent was not beneficial, the only exception being the coupling of 
hemiacetals 6 or 8 with the spacer (70% and 75% yield, respectively). 
The low yields are presumably due to the poor reactivity of H-phosphonates 17 and 18. Then 
Oscarson’s approach1 seems to be not suitable for this kind of coupling. 
Further elongation and synthesis of higher oligomers has to be performed using a different 
approach. 
A NEW SYNTHETIC ROUTE FOR TETRAMER FORMATION 
As far as the azide reduction is concerned, the “NiCl2/NaBH4” protocol led to very low yields when 
applied on pre-formed phosphodiester-linked oligomers. We therefore decided to reduce the 
azido function in a early stage of the synthesis, namely on building blocks 1 and 2 to provide N-
acetamido derivates 40 and 41, respectively, in quantitative yield (Scheme 1). 
 
Scheme 1_Acetamido key precursors: synthesis of 40 and 41, and of hemiacetals 42 and α-43. 
Hemiacetals 42 and 43 were synthesized by desilylation of corresponding building blocks using 
glacial acetic acid and tetrabutylammonium fluoride (TBAF) 1M in THF (90% and 81% yield, 
respectively). Quite surprisingly, NMR analysis showed that 42 was obtained as an α,β mixture, 
while 43 as a pure α hemiacetal (Scheme 1). Taking into account these results, first the synthesis 
of H-phosphonates 44 and 45 was tested. Only H-phosphonate 45 was obtained as an α pure 
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stereoisomer without the use of H3PO3 as equilibrating-agent, while 44 was achieved as an 
anomeric mixture (Scheme 2).  
 
Scheme 2_Synthesis of acetamido H-phosphonates. 
Since 2-N-acetamido H-phosphonates are less stable than the corresponding azido H-
phosphonates, the coupling between 43 and a stable H-phosphonate (see CHAPTER 5, “approach 
A”), i.e. 3-N-carbobenzyloxy-propanolamine H-phosphonate 14, was explored (46, 45% yield, 
Scheme 3). 
 
Scheme 3_Synthesis of alcohol acceptor 47. 
The coupling was accomplished in standard conditions, and NMR analysis confirmed the α 
configuration of the anomeric carbon. According to oligomer elongation, alcohol 47 was achieved 
by O-deacetylation of 46 (quantitative yield). 
Acceptor 47 is the key building block for the synthesis of longer oligomer, i.e. the tetramer 46: in 
Scheme 4 is reported the synthetic 1+1+2 approach we envisaged for this goal. 
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Scheme 4_Proposed 1+1+2 synthetic approach for the synthesis of tetramer 48. 
Acceptor 47 will be converted into the H-phosphonate 50, with salicylchlorophosphite in pyridine 
(Scheme 5). Then the coupling between hemiacetal 43 and H-phosphonate 50 will be 
accomplished in standard conditions, providing (according to previous results) α,α dimer 51. Dimer 
51 will be submitted to O-deacetylation to obtain 49.  
 
Scheme 5_Reactions in progress. 
On the other hand, we synthesized acceptor 55. The regioselective reductive opening of the 
benzylidene acetal in compound  40 afforded 52 (45%), followed by H-phosphonate formation at 
4-OH  to provide the stable H-phosphonate 53 in 68% yield (Scheme 6). 
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Scheme 6_Synthesis of H-phosphonate 53. 
The coupling between hemiacetal 43 and H-phosphonate 53 was accomplished in standard 
conditions (56% yield, Scheme 7). NMR spectra confirmed the α configuration of the 
phosphodiester bridge of dimer 54. 
 
Scheme 7_Synthesis of dimer 55. 
Dimer 54 was submitted to desilylation by TBAF 1M in dry THF to obtain 55 (40% yield, Scheme 7). 
NMR analysis highlighted the obtainment of only the α hemiacetal. This unexpected result will 
allow the coupling between 55 and H-phosphonate 56 (Scheme 8), to achieve tetramer 57, 
containing exclusively α phosphodiesters bridges.  
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Scheme 8_Synthesis of full protected tetramer 57: the coupling between acceptor 55 and H-phosphonate 56. 
Eventually, conventional protecting groups removal will lead to the tetramer 48 as a tetrasodium 
salt (Scheme 9).  
 
Scheme 9_Protecting group removal leads to 48. 
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CONCLUSIONS 
In summary, the synthesis of key precursors 1 and 2 was accomplished in medium (up to 2 g) and 
in large (up to 30 g) scale. 
We have explored the synthesis of synthetic oligomers via H-phosphonate approach. Accordingly 
we were able to synthesize 2-azido-2-deoxy glycosyl α-anomeric H-phosphonates (17 and 18). In 
this way, we achieved an important goal, since pure alpha 2-azido-2-deoxy glycosyl H-
phosphonates have never been reported in the literature. Following this route, we were able to 
synthesize monomer 20, dimer 26, and trimer 31. These compounds have anomerically O-linked 
aminopropyl phosphate linker at their reducing end to allow conjugation to a protein carrier. A 
significant drawback, in their synthesis from H-phosphonates 17 and 18, was the low yield of some 
crucial steps.  
Neo-glycoconjugates of monomer and dimer have been synthesized during my stage at Novartis 
(Siena). The immunogenical profile of synthetic antigens will be elucidated as a result of mice 
immunization and ELISA (Enzyme-Linked ImmunoSorbent Assay, performed to determine the 
antibody specificity) assay, that will be performed at Novartis Vaccines and Diagnostics Research 
Centre. Trimer-glycoconjugate will be synthesized in the near future. 
We tried to solve some problem of the synthetic strategy using the NH-acetamido route. The 
obtainment of alpha pure alcohols 35 and 40 was quite a surprise. On the basis of the last results, 
we envisaged the synthesis of the tetramer following a 1+1+2 approach. Work is in progress to 
achieve this goal. 
FUTURE WORK 
A problem often encountered in the formulation of fully synthetic carbohydrate-based vaccines is 
the poor chemical and/or enzymatic stability of many CPSs. This can greatly hamper the 
manufacture of conjugate vaccines, where chemical manipulation of the saccharide is an 
inevitable step so that it may be linked to the protein carrier. In the case of Men X, chemical 
lability might derive from the acetalic position of the phosphodiester bridges, as it occurs in N. 
meningiditis A CPS. Indeed, phosphodiesters are normally quite stable, but when they engage the 
anomeric position of a carbohydrate residue, the C1-O1 bond becomes much more labile due to 
the possibility of the electron pair on the ring oxygen displacing the phosphate or phosphodiester 
group. In case stability problems should emerge during natural fragments manipulation, a part of 
the present research project will be devoted to the synthesis of modified structures which, while 
keeping the immunological properties of the natural counterparts (i.e. to elicit antibodies cross-
reacting with the bacterial capsule), are endowed with an increased stability. The stability of the 
phosphodiester bridges can be increased by applying a number of structural modifications on the 
phosphodiester group. Based on our recent experience acquired on the synthesis of stable 
analogues of N. meningiditis A CPS, the most promising candidates as possible vaccine 
components can be obtained by replacing the anomeric oxygen of the phosphodiester with a 
methylene group, i.e. by replacing the phosphodiester with a phosphonoester bridge. In that 
event, fragments such as those reported in Figure 1 will be synthesised and tested. 
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Figure 1 
Finally, the synthetic oligomers endowed with the most promising biological profile will be 
conjugated to polyfunctional rigid scaffolds in order to amplify their immune response by 
exploiting the “multivalency effect”. Synthetic antigens are indeed often too small to effectively 
stimulate the immune system. It is known that, in order to be immunogenic, the saccharide chain 
needs to be composed by several monosaccharide units. On the other hand, a chemical synthesis 
of such a kind of fragments is unpractical. A possible solution is the preparation of multivalent 
compounds in which several short saccharide units are linked to a core, thus generating a system 
containing a large number of antigenic determinants, which could enhance the immune response 
acting as a mimic of the natural polymer. 
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GENERAL EXPERIMENTAL METHODS 
CHARACTERISATION OF THE PRODUCTS 
Thin Layer Chromatography 
Thin Layer Chromatography (TLC) and High Performance Thin Layer Chromatography (HPTLC) were 
performed on Merck precoated 60F254 plates (0.25 mm and 0.2 mm thickness, respectively). 
Reactions were always followed by TLC-analysis; compounds were visualized, when appropriate, 
by UV light (254 nm) and always by spraying with: 
 Molybdic solution [21 g of (NH4)4Mo4O24, 1g of Ce(SO4)2, 31 mL of H2SO4 98%, 970 mL water], or 
 Sulphuric acid [50 mL of H2SO4 98%, 450 mL of MeOH (or EtOH), 450 mL water], or 
 Ninhydrin [2.7g of 2,2-Dihydroxyindane-1,3-dione, 27 mL of AcOH, 900 mL of n-BuOH (or 
EtOH)], 
with detection by charring at 196°C. 
Unless otherwise indicated, especially during the chromatography purifications, the molybdic 
solution was the most used reagent. 
Flash chromatography 
According to Still1 procedure, compounds were purified by flash chromatography, using Silica gel 
(SiO2, high-purity grade (Merck Grade 9385), pore size 60 Å, 230-400 mesh particle size) by Sigma-
Aldrich®. 
In some cases it was also used a flash purification system, Biotage® SP1™:2 SP1 means a single-
column flash purification system [with Touch Logic Control™ and TLC-to-gradient feature designed 
to accelerate and simplify the purification process]. Available in sizes from 10 g to 340 g with 
standard (50 μm) silica, Biotage SNAP cartridges were used to purify our compounds. 
NMR analysis 
NMR spectra were recorded in a Bruker Avance 400 instrument (400, 101 and 162 MHz for 1H, 13C, 
and 31P respectively), and all were run at room temperature (298K). The samples were prepared 
using deuterated solvents, as CDCl3, D2O, CD3OD and (CD3)2SO, by Sigma-Aldrich®. 
Chemical shifts (δ) are reported in ppm scale and the coupling constants (J) in Hz. The chemical 
shift displacement is based on the residual proton in the solvent (e.g. the CHCl3, 0.01 % in 99.99 % 
CDCl3), following the solvent’s value established by Hugo E. Gottlieb and Abraham Nudelman.
3 The 
multiplicity of signals has been described as: s (singlet), d (doublet), t (triplet), m (multiplet), dd 
(doublet of doublets), dt (doublet of triplets), sept (septet). 
1H-NMR spectra were recorded for all the synthesized products. In the case of unknown structure, 
the characterization is here reported by 1H-NMR, 13C-NMR and, when relevant, by 31P-NMR: the 
registration of bidimensional (2D-COSY, 2D-HETCOR) analyses was due to better assignment of 
peaks to the structure. 
To better understand peaks assignments, two examples are reported in Figure 1: for instance, in 
the case of a dimer we called ring-A the sugar coupled with the spacer and ring-B the one at the 
non-reducing terminus. 
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Figure 1 
NMR experiments of the lyophilized fully deprotected final products [dissolved in deuterium oxide 
(D2O, 99.9% atom D, Aldrich)], were recorded at 25°C on a Brucker Avance III 400 MHz 
spectrometer at Novartis Vaccines and Diagnostics Research Center. 
Mass analysis 
ESI mass were recorded in negative or positive modes on Jeol AX-505 and for high resolution on 
Bruker Daltonics APEX™ II (FT-ICR) instrument belonging to CIGA.4 
MALDI-TOF mass spectra of CRM197, HSA and glycoconjugates were recorded by UltraFlex III 
MALDI-TOF/TOF instrument (Bruker Daltonics). 
Optical rotatory power 
Optical rotations were measured at r.t. with Pelkin-Elmer 241 polarimeter (589 nm, D line from 
sodium lamp); the polarimeter tube was 100 mm thick and 1 ml of capacity. Optical rotatory 
powers were measured following the equation: 
specific rotation = 
cl
α10000
 
where α is the observed rotation (on the average of 15 experimental values), l is the length of the 
observed layer in mm, c is the number of g of substance contained in 100 ml of solution. The 
optical rotation (α) can be expressed in angular degrees: values are given in 10-1 deg cm2 g-1 unit. 
SOLVENT CONDITIONS 
ANHYDROUS ENVIRONMENT 
Unless otherwise indicated, all the reaction were conducted under nitrogen atmosphere. When 
stirred overnight, the reaction were put in anhydrous atmosphere by an Argon-balloon. 
SOLVENT CONDITIONS 
Unless otherwise indicated, all the reactions were performed using dry solvents: DCM, MeOH, 
pyridine, toluene, DMF, CH3CN and THF were purchased over molecular sieves from Sigma-
Aldrich® and used without further purifications. 
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GENERAL PROCEDURES 
A. DESILYLATION5 
Glacial acetic acid (3 eq) and Tetrabutylammonium fluoride (3 eq) 1M in THF solution (10 
mL/mmol) were sequentially added to a solution of the sugar in anhydrous THF at -40°C. After 
completion of the reaction, the mixture was warmed up to r.t., poured in DCM, and washed three 
times with brine. The organic layer was dried (Na2SO4), filtered and concentrated. The residue was 
purified by column chromatography. 
B. REGIOSELECTIVE/REDUCTIVE OPENING OF BENZYLIDENE ACETAL6 
The sugar was dissolved in dry DCM (5 mL/mmol) and Et3SiH (5 eq) was added dropwise. After 30 
min, the mixture is cooled to 0 °C, and TFA (5 eq) was slowly added. The reaction was stirred at r.t. 
and, after completion, diluted with DCM, quenched by addiction of a saturated aqueous solution 
of NaHCO3. The aqueous phase was extracted with DCM, the combined organic phases were dried 
over Na2SO4 and the solvent removed under reduced pressure. The crude product was purified by 
flash chromatography. 
C. ZEMPLEN REACTION7 
The reactant was dissolved in dry methanol and stirred under nitrogen. A solution of 
NaOMe/MeOH 0.1 M (or 0.05 M) was added dropwise until basic pH. After deacetylation, 
confirmed by TLC, the reaction was neutralized by IRA120-H+ ion-exchange resin (Amberlite® 
IR120, hydrogen form, 16-50 mesh, exchange capacity = 1.9 meq/mL, by Sigma-Aldrich®), filtered 
and concentrated. 
D. α ANOMERIC H-PHOSPHONATE 
H3PO3 was coevaporated three times with dry toluene, and dried by high vacuum pump. A 2M 
solution in pyridine of H3PO3 (3 eq) was dropped to a solution of the hemiacetal in dry pyridine (4 
mL/mmol), and thereafter the solution was cooled to 0°C and salicyl chlorophosphite was slowly 
added. The reaction was stirred at r.t. and, after disappearance of the starting material (over 
night), the reaction temperature was raised up to +40°C and the mixture was stirred under argon 
until complete disappearance of the β anomer (verified by 1H- and 31P-NMR spectra). 1M solution 
of TEAB (4 mL/mmol) was added to the reaction at r.t. and, the mixture was diluted with CH2Cl2, 
washed three times with cold TEAB (0.5 M), dried (Na2SO4), filtered and concentrated. The crude 
was purified by flash chromatography (DCM:MeOH + 1% TEA). The H-phosphonate has to be 
stabilized, washing with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the 
purified product. 
E. STANDARD PROCEDURE FOR PHOSPHODIESTER SYNTHESIS 
The donor (H-phosphonate, 1.2 eq) and the acceptor (alcohol, 1 eq) are first co-evaporated three 
times with dry pyridine or dry toluene, thereafter they are dried by high vacuum pump overnight. 
The reactants were dissolved in pyridine (10 mL/mmol), then pivaloyl chloride (2.5 eq) was added 
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dropwise and the reaction mixture was stirred under nitrogen. The reaction completion was 
monitored by TLC (or HPTLC). After cooling to -40°C, a freshly prepared 0.5 M solution of iodine 
(2.5 eq) in pyridine/water 19:1 was added. The oxidation was completed at 0°C and quenched by 
dropwise addition of a 0.5 M solution of Na2S2O3 · 5H2O  (10% w/v). The mixture was diluted with 
CH2Cl2, washed two times with Na2S2O3 · 5H2O (0.5 M), then with cold TEAB (0.5 M), dried 
(Na2SO4), filtered and concentrated. The crude was purified by flash chromatography (DCM:MeOH 
+ 1% TEA). The phosphate bridge has to be stabilized, washing with 0.25M cold TEAB [then drying 
(Na2SO4), filtering and concentrating] the purified product. 
F. AZIDE REDUCTION BY NaBH4/NiCl2·6H2O
8 
To a mixture of azide-containing compound (1 eq) and NiCl2·6H2O (3 eq) in MeOH (10 mL/mmol), 
under stirring and N2 atmosphere, NaBH4 (8 eq) was added at 0 °C in small portion (1 hour). The 
formation of a black precipitate indicated the formation of a Ni-B species. The mixture was stirred 
at 0 °C and, after consumption of the starting material (amine formation is monitored by 
Ninhydrin-detection), Ac2O (20eq) was added. The mixture was concentrated under reduced 
pressure, diluted with CH2Cl2 and washed three times with water. The organic phase was dried 
(Na2SO4), concentrated, and purified by flash chromatography to give the pure acetamide. 
G.HYDROGENATION CATALYZED BY PALLADIUM 
The sugar was dissolved in a 5:1 solution of methanol/water, then a catalytic amount of Pd/C 
(10%) was added. The reaction mixture was vigorously stirred under H2 atmosphere at r.t. 
overnight. The solution was then filtered over a celite pad, and finally concentrated under 
reduced pressure. 
H. ION EXCHANGE 
The ion exchange (from +NHEt3 to 
+Na) of the final products was carried out using a 
strong resin, the commercially available DOWEX® 50WX8 (H+ form, 50-100 mesh, 
exchange capacity = 1.7 meq/mL, by Sigma-Aldrich®). 
Two distinct portions of resin were activated by washing with a 5% aqueous 
solution of HCl (+H) and with a 5% aqueous solution of NaOH (+Na).  
The equation reported below was used to calculate the required volume of 
regenerant. 
y
v
w
%1000
100MWcapacity exchange(mL) x
(mL) V
regenerant
regenerantresinresin
regenerant
 
The variable y is equal to 4 for strong resin, like in this case, and 2 for weak resin. 
Regenerants were introduced into the flask containing the resin, the contact time 
had to be at least 1 hour: the two portion of resin were incubated independently 
and mixed by a  digital shaker (Heidolph© Promax 1020). The product was eluted 
continuously very slowly and directly was exchanged from +NHEt3 first to H
+ and 
then to Na+, as depicted in (Figure 2).  
Figure 2 
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2-Azido-2-deoxy-α/β-D-glucopyranose (3) 
 
Synthetic procedure 
Preparation of TfN3:  
DCM (250 mL) was added to a solution of NaN3 (59.5 g, 0.92 mol) in water (150 mL) at 0°C. The 
mixture was stirred vigorously and treated with trifluoromethanesulfonic anhydride (31.0 mL, 0.19 
mol) over a period of 3 hours at 0°C. After the complete addition of Tf2O, the reaction mixture was 
stirred at 0°C for 2.5 hours. The aqueous phase was extracted with DCM (2x100 mL) and the 
combined organic layers washed with saturated Na2CO3. The reaction volume was reduced until 
100 mL and used directly in the diazotransfer step. 
CAUTION: dry TfN3 is explosive at high temperature! 
Diazotransfer reaction: 
CuSO4 (140 mg, 0.88 mmol) and K2CO3 (19.2 g, 0.14 mol) were added to a solution of D-
glucosamine hydrochloride (20.0 g, 0.092 mol) in water (300 mL). Methanol (600 mL) was added 
followed by the addition of the TfN3 solution. The clear blue solution was allowed to stir for 24 
hours at RT. The solvents were removed in vacuum to afford product 3 as a brown crude, without 
any further purification. 
The reaction was performed also in large scale (up to 30 g). 
Product characterization 
Formula C6H11N3O5 
Molecular Weight 205.17 g/mol 
TLC conditions Rf (DCM/MeOH 7:3) 0.64 
The spectroscopic data were in agreement with those reported in literature.9  
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Thexyldimethylsilyl 2-Azido-4,6-O-benzylidene-2-deoxy-β-D-
glucopyranoside (5) 
 
Synthetic procedure 
Compound 3 (5 g, 24.37 mmol) was dissolved in dry DMF (100 mL) and benzaldehyde 
dimethylacetal (11 mL, 73.11 mmol) was added, followed by addition of camphorsulfonic acid 
(pH≈5). The reaction was heated at 40°C for 48  hours, then it was quenched by adding NaHCO3 
until neutral pH and solvents were removed under vacuum. 
The resulting product, without any further purification, was dissolved in dry DCM (25 mL) and cooled to -10 
°C. Imidazole (4.15 g, 60.92 mmol) and TDSCl (5.32 mL, 26.81 mmol) were added to the cooled solution and 
the mixture stirred 24 hours. The reaction, diluted with DCM, was quenched by adding water. The aqueous 
phase was extracted with DCM (3x200 mL), the combined organic phases were dried over Na2SO4 and the 
solvent removed under reduced pressure. The crude product was purified by flash chromatography (H/EA 
gradient) yielded 5 (yellow oil, 6.9 g, 15.84 mmol, 65% over three steps), only in β configuration. 
Product 4 characterization 
Formula C13H15N3O5 
Molecular Weight 293.28 g/mol 
TLC conditions Rf (DCM/MeOH 95:5) 0.35 
Product 5 characterization 
Formula C21H33N3O5Si 
Molecular Weight 435.59 g/mol 
TLC conditions Rf (H/EA 9:1) 0.25 
The spectroscopic data were in agreement with those reported in literature.10  
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Thexyldimethylsilyl 2-Azido-3-O-benzyl-4,6-O-benzylidene- 
2-deoxy-β-D-glucopyranoside (1) 
 
Synthetic procedure 
Compound 5 (11.79 g, 27.1 mmol) was dissolved in dry DMF (100 mL) and BnBr (6.4 mL, 54.1 
mmol) and catalytic amount of TBAI (2.5 g, 6.8 mmol) were added to the solution. NaH 95% (974 
mg, 40.6 mmol) was slowly added and reaction mixture was stirred at RT for 1 hour. The reaction 
was quenched by adding MeOH then the solvents were removed under vacuum. The residue was 
dissolved in EtOAc (200 mL) and washed two times with 5% solution of HCl (2x200 mL) and with 
brine (1x200 mL). The organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (H/EA gradient) affording 1 
(10.68g, 20.31 mmol,72% yield) as a white solid. 
Product characterization 
Formula C28H39N3O5Si 
Molecular Weight 525.71 g/mol 
TLC conditions Rf (H/EA 95:5) 0.30 
The spectroscopic data were in agreement with those reported in literature.11  
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2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranose (6) 
 
Synthetic procedure 
Compound 1 (5.47 g, 9.97 mmol) was treated as described in the General Procedure A. Product 6 
was obtained as an α:β mixture (3.06 g, 7.98 mmol, white solid, 80% yield). 
Product characterization 
Formula C20H21N3O5 
Molecular Weight 383.40 g/mol 
TLC conditions Rf (H/EA 7:3) 0.31 
The spectroscopic data were in agreement with those reported in literature.12 
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Thexyldimethylsilyl 2-Azido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranoside (7) 
 
Synthetic procedure 
Compound 1 (4.07 g, 7.74 mmol) was treated as described in the General Procedure B. Product 7 
was obtained as white solid (3.49 g, 6.61 mmol, 85% yield). 
Product characterization 
Formula C28H41N3O5 
Molecular Weight 527.73 g/mol 
TLC conditions Rf (H/EA 9:1) 0.25 
The spectroscopic data were in agreement with those reported in literature.13 
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Thexyldimethylsilyl 4-O-Acetyl-2-azido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranoside (2) 
 
Synthetic procedure 
Compound 7 (2.73 g, 5.18 mmol) was dissolved in dry pyridine (50 mL) and the solution was 
cooled to 0°C. Acetic anhydride (987 µL, 10.36 mmol) was added dropwise, followed by a catalytic 
addition of DMAP. The mixture was stirred at r.t. until completion. Then, the reaction was 
concentrated under reduced pressure and the obtained residue was diluted with EtOAc (100 mL) 
and washed with 5% solution of HCl (1x100 mL),  saturated solution of NaHCO3 (1x100 mL) and 
brine (1x100 mL). The first aqueous phase was extracted with DCM (1x100 mL) and the combined 
organic phases were dried over Na2SO4 and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (H/EA gradient) affording 2, as a white solid (2.70 g, 
4.74 mmol, white solid, 92% yield). 
Product characterization 
Formula C30H43N3O6 
Molecular Weight 569.76 g/mol 
TLC conditions Rf (H/EA 85:15) 0.45 
Optical rotation 
25
D
- 28.98 (c = 1 in CHCl3) 
HRMS (ESI) 
Experimental m/z: 592.28077 [M+Na]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ(ppm): 7.38 – 7.24 (m, 10H, Ar), 5.03 – 4.91 (m, 1H, H-4), 4.81 (d, J = 
11.5 Hz, 1H, ½ CH2Ph), 4.62 (d, J = 11.5 Hz, 1H, ½ CH2Ph), 4.53 (dd, JH-1, H-2 = 5.4 Hz, JH-1, H-3 = 2.2 Hz, 
1H, H-1 β), 4.51 (s, 2H, CH2Ph), 3.57 – 3.47 (m, 3H, H-6, H-6’, H-5), 3.41 – 3.34 (m, 2H, H-3, H-2), 
1.85 (s, 3H, CH3CO), 1.68 (ept, J = 7.0 Hz, 1H, CH TDS), 0.92 (s, 3H, CH3 TDS), 0.90 (s, 9H, CH3 TDS), 
0.22 (s, 3H, CH3Si TDS), 0.21 (s, 3H, CH3Si TDS). 
13C NMR (101 MHz, CDCl3) δ(ppm): 169.82 (CO), 138.13 (Cq Ar), 138.10 (Cq Ar), 128.57, 128.47, 
128.01, 127.95, 127.82, 127.77 (CH Ar), 97.15 (C-1), 80.49 (C-3), 74.87 (CH2Ph), 73.75 (CH2Ph), 
73.64 (C-5), 71.25 (C-4), 70.06 (C-6), 68.70 (C-2), 34.12 (CH TDS), 25.03 (Cq TDS), 20.94 (CH3CO), 
20.15, 20.05 , 18.66, 18.56 (4 CH3 TDS), -1.89, -3.09 (2 CH3Si TDS).  
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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4-O-Acetyl-2-azido-3,6-di-O-benzyl-2-deoxy-α/β-D-glucopyranose (8) 
 
Synthetic procedure 
Compound 2 (2.70 g, 4.74 mmol) was treated as described in the General Procedure A. Product 8 
was obtained as an α:β (2.64:1) mixture (1.90 g, 4.44 mmol, white solid, 94% yield). 
Product characterization 
Formula C22H25N3O6 
Molecular Weight 427.45 g/mol 
TLC conditions Rf (H/EA 7:3) 0.33 
MS (ESI) 
m/z (%): 450.5 (100) [M+Na]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ(ppm): 7.38 – 7.24 (m, Ar), 5.31 (t, JH-1, H-2 = JH-1, H-3 2.9 Hz, 1H, H-1 α), 
5.01 (dd, JH-4, H-3 = 10.1, JH-4, H-5 = 9.3 Hz, 1H, H-4 α), 4.95 (m, 1H, H-4 β), 4.83 (d, J = 11.1 Hz, 1H, ½ 
CH2Ph α), 4.81 (d, J = 11.4 Hz, 1H, ½ CH2Ph β), 4.64 (d, J = 11.1 Hz, 1H, ½ CH2Ph α), 4.61 (d, J = 11.4 
Hz, 1H, ½ CH2Ph β), 4.60 – 4.55 (m, 1H, H-1 β), 4.51 (s, 4H, CH2Ph β, CH2Ph α), 4.19 – 4.10 (m, 1H, 
H-5 α), 4.04 – 3.92 (m, 1H, H-3 α), 3.60 – 3.37 (m, 8H, H-5 β, H-6 β, H-6’ β, 2 H-6 α, H-6’ α, H-2 β, 
H-2 α, H-3 β), 1.87 (s, 3H, CH3CO α), 1.84 (s, 3H, CH3CO β). 
 
13C NMR (101 MHz, CDCl3) δ 169.82 (CO β), 169.81 (CO α), 137.80, 137.66 (Cq Ar β, Cq Ar α), 
128.67, 128.63, 128.57, 128.54, 128.24, 128.19, 128.11, 128.07, 128.02, 127.97 (CH Ar β, CH Ar α), 
96.33 (C-1 β), 92.08 (C-1 α), 80.51 (C-3 β), 77.80 (C-3 α), 75.03, 73.73 (CH2Ph β, CH2Ph α), 73.67 (C-
5 β), 71.28 (C-4 α), 70.77 (C-4 β), 69.33 (C-5 α), 69.26 (C-6 β, C-6 α), 67.21 (C-2 β), 63.73 (C-2 α), 
20.90 (CH3CO β, CH3CO α). 
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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Imidazole-1-sulfonyl azide hydrochloride (9) 
 
Synthetic procedure 
Sulfuryl chloride (16.2 mL, 200 mmol) was added dropwise to an ice-cooled suspension of NaN3 
(13.0 g, 200 mmol) in acetonitrile (200 mL) and the mixture stirred overnight at room 
temperature. Imidazole (25.9 g, 380 mmol) was added portion-wise to the ice-cooled mixture and 
the resulting slurry stirred at r.t. for 3 h. The mixture was diluted with EtOAc (400 mL), washed 
with H2O (2×400 mL) then saturated aqueous NaHCO3 (2×400 mL), dried over Na2SO4 and filtered. 
A solution of HCl in EtOH [obtained by the dropwise addition of AcCl (21.3 mL, 300 mmol) to ice-
cooled dry ethanol (75 mL)] was added dropwise to the filtrate while stirring, the mixture chilled 
in an ice-bath, filtered and the filter cake washed with EtOAc (3×100 mL) to give 9 as white 
needles powder (32.26 g, 154 mmol, 77%). 
Product characterization 
Formula C3H4ClN5O2S 
Molecular Weight 209.61 g/mol 
The spectroscopic data were in agreement with those reported in literature.14 
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2-Azido-2-deoxy-α/β-D-glucopyranose (3) 
 
Procedure 
Imidazole-1-sulfonyl azide hydrochloride 9 (4.6 g, 22 mmol) was added at 0°C to the D-glucosamine 
hydrochloride (3.3 g, 18.3 mmol), K2CO3 (5.8 g, 42.09 mmol)
 
and CuSO4 pentahydrate (55 mg, 
0.183 mmol) in MeOH (91 mL) and the mixture was stirred at room temperature for 3 hours.
 
The 
solution was neutralized with conc. HCl (dropwise addition) and concentrated under reduced 
pressure. Flash chromatography gave the azide 3 (4.24 g, 20.68 mmol, 94%). 
Product characterization 
Formula C6H11N3O5 
Molecular Weight 205.17 g/mol 
TLC conditions Rf (DCM/MeOH 7:3) 0.64 
The spectroscopic data were in agreement with those reported in literature.15 
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1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose (10) 
 
Procedure 
Imidazole-1-sulfonyl azide hydrochloride 9 (11.75 g, 56.04 mmol) was added at 0°C to the D-
glucosamine hydrochloride (10.07 g, 46.7 mmol), K2CO3 (17.43 g, 126.1 mmol)
 
and CuSO4 
pentahydrate (140 mg, 0.467 mmol) in MeOH (234 mL) and the mixture was stirred at room 
temperature for 3 hours.
 
The solution was concentrated and co-evaporated with toluene (2x100 
mL). Acetic anhydride (35.6 mL, 373.6 mmol) and a catalytic amount of DMAP were added to the 
residue in pyridine (120 mL) and the mixture was stirred for 3 hours, then concentrated, diluted 
with water (500 mL) and extracted three times with DCM (3x500 mL). The combined organic 
layers were dried (Na2SO4), filtered and concentrated. Flash chromatography gave the azide 10 
(13.41 g, 35.92 mmol, 77%). 
Product characterization 
Formula C14H19N3O9 
Molecular Weight 373.32 g/mol 
TLC conditions Rf (H/EA 6:4) 0.53 
The spectroscopic data were in agreement with those reported in literature.15,16  
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose (11) 
 
Procedure 
Freshly prepared 2M solution of hydrazine acetate [NH2NH2·H2O (1.5mL, 29.20 mmmol), AcOH (1.4 
mL, 22.46 mmol) and dry MeOH (15.6 mL)] was dropwise added to a solution of 10 (8.38 g, 22.46 
mmol) in dry DMF (100 mL) at 0°C. The mixture was stirred at r.t. for 2 hour.
 
The mixture was 
concentrated, diluted with EtOAc (300 mL) and extracted with water (3x300 mL). The organic layer 
was dried (Na2SO4), filtered, concentrated and finally purified by flash chromatography. Product 
11 was obtained as an α:β mixture (6.7 g, 20.21 mmol, 90% yield). 
Product characterization 
Formula C12H17N3O8 
Molecular Weight 331.28 g/mol 
TLC conditions Rf (H/EA 6:4) 0.43 
The spectroscopic data were in agreement with those reported in literature.17 
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Thexyldimethylsilyl 3,4,6-Tri-O-acetyl-2-azido-2-deoxy-β-D-
glucopyranoside (12) 
 
Procedure 
Hemiacetal 11 (10.37 g, 31.3 mmol) was dissolved in dry DMF (150 mL) and cooled to 0°C, then 
imidazole (6.39 g, 93.9 mmol) and TDSCl (9.2 mL, 46.9 mmol) were added. The mixture was stirred 
24 hours. The reaction was concentrated to eliminate as much as possible the DMF. The crude 
was diluted by EtOAc (200 mL) and washed with water (2 x 300 mL) and brine (300 mL). The 
organic phase was dried over Na2SO4 and the solvent removed under reduced pressure. Flash 
chromatography gave 12 as a yellow solid (11.39 g, 21.11 mmol, 73%). 
Product characterization 
Formula C20H35N3O8Si 
Molecular Weight 473.59 g/mol 
TLC conditions Rf (H/EA 7:3) 0.32 
The spectroscopic data were in agreement with those reported in literature.18 
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Thexyldimethylsilyl 2-Azido-4,6-O-benzylidene-2-deoxy-β-D-
glucopyranoside (5) 
 
Synthetic procedure 
Compound 12 (6.11 g, 12.9 mmol) was treated as described in the General Procedure C. Crude 13 
(4.48 g, 12.9 mmol) was diluted in dry acetonitrile (130 mL) and benzaldheyde dimethylacetal (5.8 
mL, 38.7 mmol) was added, followed by addition of camphorsulfonic acid (pH≈5). The reaction was 
vigorously stirred at r.t. for 3 days, then it was quenched by dropwise addition of TEA until neutral 
pH and solvents were removed under vacuum. The crude was purified by flash chromatography 
(H/EA gradient) yielded 5 (3.56 g, 8.17 mmol, 63% over two steps). 
Product 13 characterization 
Formula C14H29N3O5Si 
Molecular Weight 347.48 g/mol 
TLC conditions Rf (H/EA 1:1) 0.27 
The spectroscopic data were in agreement with those reported in literature.19 
Product 5 characterization 
Formula C21H33N3O5Si 
Molecular Weight 435.59 g/mol 
TLC conditions Rf (H/EA 9:1) 0.25 
The spectroscopic data were in agreement with those reported in literature.10  
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3-N-Carbobenzyloxy-aminopropyl Hydrogen-phosphonate (14), 
triethylammonium salt  
 
Synthetic procedure 
The H3PO3 (973 mg, 11.87 mmol) and the commercially available 3-N-Cbz-aminopropanol (2.07 g, 
9.89 mmol) were mixed and co-evaporated three times with dry pyridine (10 mL), then dried in 
vacuum overnight. The reactants were dissolved in pyridine (50 mL), pivaloyl chloride (1.5 mL, 
11.87 mmol) was added dropwise and the reaction is stirred for 30 min: then TEAB 1M (40 mL) 
was added. The solvents were removed under reduced pressure and the crude was purified by 
flash chromatography (2.77 g, 7.42 mmol, 75%). 
Product characterization 
Formula C17H31N2O5P 
Molecular Weight 374.41 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.34 
The spectroscopic data were in agreement with those reported in literature.20  
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2-Azido-3-O-benzyl-4,6-O-benzilydene-2-deoxy-α-D-glucopyranosyl 
Hydrogen-phosphonate (17), triethylammonium salt 
 
Synthetic procedure 
Compound 6 (168 mg, 0.44 mmol) was treated as described in the General Procedure D. After 12 
days the NMR analysis (1H- and 31P-NMR) highlighted the disappearance of the β anomer. Product 
17 α was obtained in 41% yield (98 mg, 0.18 mmol). 
The reaction was performed also in medium-large scale (up to 1 g). 
In large scale,  the reaction time raised up and the yield of the by-product of hydrolysis increased. 
Product characterization 
Formula C26H37N4O7P 
Molecular Weight 548.57 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.38 
Optical rotation 
25
D
+ 10.42 (c = 1 in CHCl3) 
MS (ESI) 
Experimental m/z (%): 446.3 (35) [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.55-7.22 (m, 10H, Ar), 7.01 (d, JH-P,P = 640.4 Hz, 1H, H-P), 5.70 (dd, JH-
1,P = 8.8, JH-1,H-2 = 3.5 Hz, 1H, H-1), 5.55 (s, 1H, CHPh), 4.92 (d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.76 (d, J = 
11.1 Hz, 1H, ½ CH2Ph), 4.25 (dd, JH-6, H-6’ = 9.8, JH-6’,H-5 = 4.9 Hz, 1H, H-6), 4.21 – 4.14 (m, 1H, H-5), 
4.11 (t, JH-3,H-2 = JH-3,H-4 = 9.8 Hz, 1H, H-3), 3.71 (t, JH-4,H-3 = JH-4,H-5 = JH-6’,H-6 = JH-6’,H-5 = 9.8 Hz, 2H, H-4, 
H-6’), 3.47 (ddd, JH-2,H-3 = 9.8, JH-2,H-1 = 3.5, JH-2,P = 1.3 Hz, 1H, H-2). 
 
31P NMR (162 MHz, CDCl3) δ 1.84. 
 
13C NMR (101 MHz, CDCl3) δ 138.12, 137.52 (Cq Ar), 129.09, 128.44, 128.34, 128.28, 127.86, 126.21 
(CH Ar), 101.65 (CHPh), 93.77 (C-1), 82.89 (C-4), 76.34 (C-3), 74.92 (CH2Ph), 69.01 (C-6), 63.65 (C-
2), 63.55 (C-5).  
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1H (400 MHz, CDCl3): 
 
31P (162 MHz, CDCl3): 
 
H-1 α                       H-1hydrolysis-product   H-1 β                
 P β                    P α                
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4-O-Acetyl-2-azido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl 
Hydrogen-phosphonate (18), triethylammonium salt 
 
Synthetic procedure 
Compound 8 (368.1 mg, 0.86 mmol) was treated as described in the General Procedure D. The 
disappearance of the β anomer was monitored by NMR (1H and 31P) and was achieved in 6 days. 
Product 18 was obtained in 52% yield (265 mg, 0.44 mmol). 
The reaction was performed also in medium-large scale (up to 2 g). 
In large scale, the time reaction raised up and the yield of the by-product of hydrolysis increased. 
Product characterization 
Formula C28H41N4O8P 
Molecular Weight 592.62 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.44 
Optical rotation 
25
D
+ 9.67 (c = 1.1 in CHCl3) 
MS (ESI) 
Experimental m/z (%): 490.3 (35) [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.38 – 7.19 (m, 10H, Ar), 7.03 (d, JH-P,P = 642.0 Hz, 1H, H-P), 5.73 (dd, JH-
1,P = 8.7, JH-1,H-2 = 3.0 Hz, 1H, H-1), 5.14 (t, JH-4,H-3 = JH-4,H-5 = 9.7 Hz, 1H, H-4), 4.79 (d, J = 11.1 Hz, 1H, 
½ CH2Ph), 4.60 (d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.46 (q, J = 11.8 Hz, 2H, CH2Ph), 4.19 (m, 1H, H-5), 
4.05 (t, JH-3,H-2 = JH-3,H-4 = 9.7 Hz, 1H, H-3), 3.57 – 3.38 (m, 3H, H-6, H-6’, H-2), 1.83 (s, 3H, CH3CO). 
 
31P NMR (162 MHz, CDCl3) δ (ppm): 2.24. 
 
13C NMR (101 MHz, CDCl3) δ 169.67 (CH3CO), 137.95, 137.88 (Cq Ar), 128.51, 128.37, 128.05, 
128.03, 128.00, 127.89, 127.69 (CH Ar), 93.14, 93.11 (C-1), 78.00 (C-3), 74.77 (CH2Ph), 73.59 
(CH2Ph), 70.96 (C-4), 70.21 (C-5), 68.98 (C-6), 63.60, 63.54 (C-2), 20.85 (CH3CO). 
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1H (400 MHz, CDCl3): 
 
31P (162 MHz, CDCl3): 
  
H-1 α            H-1hydrolysis-product                         H-1 β                
 P α                    P β                
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(2-Azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate) (15), 
triethylammonium salt 
 
Synthetic procedure 
H-phosphonate 17 (145.3 mg, 0.26 mmol, 1 eq) and 3-N-Cbz-propanolamine (136 mg, 0.65 mmol, 
5 eq) are first co-evaporated three times with dry pyridine, thereafter they are dried by high 
vacuum pump overnight. The reactants were dissolved in dry pyridine (1.3 mL), then pivaloyl 
chloride (40 µL, 0.325 mmol, 2.5 eq) was added dropwise at 0°C and the reaction mixture was 
stirred under nitrogen at r.t.. The reaction completion was monitored by HPTLC (DCM:MeOH 9:1). 
After cooling to -40°C, a freshly prepared 0.5 M solution of iodine (2.5 eq) in pyridine/water 19:1 
(2 mL) was added. The oxidation was completed at 0°C and quenched by dropwise addition of a 
0.5 M solution of Na2S2O3 · 5H2O  (10% w/v, 10 mL). The mixture was diluted with DCM (50 mL), 
washed two times with Na2S2O3 · 5H2O (0.5 M, 2x50 mL), then with cold TEAB (0.5 M, 1x25 mL), 
dried (Na2SO4), filtered and concentrated. The crude was purified by flash chromatography 
(DCM:MeOH + 1% TEA). The phosphate bridge has to be stabilized, washing with 0.25M cold TEAB 
[then drying (Na2SO4), filtering and concentrating] the purified product. Product 15 (122.4 mg, 
0.16 mmol, 62% yield) is obtained as a pure-α anomer. 
Product characterization 
Formula C37H50N5O10P 
Molecular Weight 755.79 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.36 
Optical rotation 
25
D
+ 11.06 (c = 1 in CHCl3) 
HRMS (ESI) 
Experimental m/z: 653.20169 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.43 (m, 2H, Ar), 7.42 – 7.23 (m, 13H, Ar), 6.18 (t, J = 5.3 Hz, 1H, 
NHCbz), 5.65 (dd, JH-1,P = 7.5, JH-1,H-2 = 3.5 Hz, 1H, H-1), 5.55 (s, 1H, CHPh), 5.06 (s, 2H, CH2Ph), 4.93 
(d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.76 (d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.24 (dd, JH-6,H-6’ = 10.1, JH-6’,H-5 = 4.9 
Hz, 1H, H-6), 4.20 – 3.94 (m, 4H, H-5, H-3, CH2O LINKER), 3.70 (t, JH-4,H-3 = JH-4,H-5 = JH-6’,H-6 = JH-6’,H-5 = 
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9.3 Hz, 2H, H-4, H-6’), 3.51 – 3.43 (ddd, JH-2,H-3 = 9.8, JH-2,H-1 = 3.5, JH-2,P = 2.3 Hz, 1H, H-2), 3.35 (dd, J 
= 11.7, 5.9 Hz, 2H,CH2NH LINKER), 1.83 – 1.72 (m, 2H, CH2 LINKER). 
 
31P NMR (162 MHz, CDCl3) δ -0.84. 
 
13C NMR (101 MHz, CDCl3) δ 156.71 (CO), 138.11, 137.49, 137.15 (Cq Ar), 129.13, 128.53, 128.47, 
128.38, 128.33, 128.03, 127.90, 126.22 (CH Ar), 101.64 (CHPh), 94.65 (C-1), 82.85 (C-4), 76.30 (C-
3), 74.95 (C-6), 69.07 (CH2Ph), 66.49 (CH2Ph), 63.72 (C-2), 63.56 (C-5), 63.04 (CH2O LINKER), 37.46 
(CH2NH LINKER), 30.45 (CH2 LINKER). 
 
 
 
 
 
 
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(2-Acetamido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate) (19), 
triethylammonium salt  
 
Synthetic procedure 
Azide 15 (97.1 mg, 0.13 mmol) was converted into acetamide 19 (13 mg, 0.017 mmol, 13% yield) 
as described in the General Procedure F. The phosphate bridge has to be stabilized, washing with 
0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the purified product. 
Product characterization 
Formula C39H54N3O11P 
Molecular Weight 771.83 g/mol 
TLC conditions Rf (EA/MeOH 9:1) 0.11 
Rf (EA/MeOH 8:2) 0.60 
Rf (MeCN/MeOH/H2O 10:1:1) 0.48 
Optical rotation 
25
D
+ 31.24 (c = 0.4 in MeOH) 
MS (ESI) 
Experimental m/z: 699.4 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.44 (m, 2H, Ar), 7.44 – 7.20 (m, 13H, Ar), 6.76 (d, J = 9.9 Hz, 
1H, NHAc), 5.99 (t, J = 5.5 Hz, 1H, NHCbz), 5.56 (s, 1H, CHPh), 5.47 (dd, JH-1,P = 7.2, JH-1,H-2 = 3.5 Hz, 
1H, H-1), 5.05 (s, 2H, CH2Ph), 4.88 (d, J = 12.1 Hz, 1H, ½ CH2Ph), 4.66 (d, J = 12.1 Hz, 1H, ½ CH2Ph), 
4.36 – 4.27 (m, 1H, H-2), 4.21 (dd, JH-6,H-6’ = 10.2, JH-6,H-5 = 4.9 Hz, 1H, H-6), 4.10 – 4.02 (m, 1H, H-4), 
4.02 – 3.87 (m, 2H, CH2O LINKER), 3.86 – 3.68 (m, 3H, H-3, H-5, H-6’), 3.32 (dd, J = 12.3, 6.2 Hz, 2H, 
CH2NH LINKER), 1.91 (s, 3H, NHCOCH3), 1.81 – 1.71 (m, 2H, CH2 LINKER). 
31P NMR (162 MHz, CDCl3) δ -0.49.
 
13C NMR (101 MHz, CDCl3) δ 156.71 (CO), 138.11, 137.49, 137.15 (Cq Ar), 129.13, 128.53, 128.47, 
128.38, 128.33, 128.03, 127.90, 126.22 (CH Ar), 101.64 (CHPh), 94.65 (C-1), 82.85 (C-4), 76.30 (C-
3), 74.95 (C-6), 69.07 (CH2Ph), 66.49 (CH2Ph), 63.72 (C-2), 63.56 (C-5), 63.04 (CH2O LINKER), 37.46 
(CH2NH LINKER), 30.45 (CH2 LINKER). 
“Synthesis and conjugation of Neisseria Meningitidis X Capsular Polysaccharide Fragments“ 
Experimental Section 
 
 
C
H
A
P
TE
R
 9
: 3
-(
N
-C
ar
b
o
b
en
zy
lo
xy
)a
m
in
o
p
ro
p
yl
 1
-O
-(
2
-A
ce
ta
m
id
o
-3
-O
-b
en
zy
l-
4
,6
-O
-b
en
zy
lid
en
e-
2
-d
eo
xy
-α
-D
-g
lu
co
p
yr
an
o
sy
l p
h
o
sp
h
at
e
) 
(1
9
),
 
tr
ie
th
yl
am
m
o
n
iu
m
 s
al
t 
111 
 
1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
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3-aminopropyl 1-O-(2-Acetamido-2-deoxy-α-D-glucopyranosyl 
phosphate) (20), sodium salt  
 
Synthetic procedure 
Fully protected acetamide 19 (13 mg, 0.017 mmol) was submitted to hydrogenation as described 
in the General Procedure G. Final monomer 20 (6.5 mg, 0.016 mmol, 62% yield) is obtained as 
sodium salt after ion exchange (see General Procedure H). 
Product characterization 
Formula C11H22N2NaO9P 
Molecular Weight 380.3 g/mol 
Optical rotation 
25
D
+ 66.00 (c = 0.11 in H2O) 
HRMS (ESI) 
Experimental m/z (%): 357.10632 [M]- 
 381.10368 [M+H]+ 
 403.08561 [M+H+Na]2+ 
NMR 
1H NMR (400 MHz, D2O) δ 5.43 (dd, JH-1,P = 7.4, JH-1,H-2 = 3.3 Hz, 1H), 4.03 – 3.73 (m, 7H, CH2O LINKER, 
H-2, H-6, H-6’, H-3, H-5), 3.51 (t, JH-4,H-3 = JH-4,H-5 = 9.3 Hz, 1H, H-4), 3.20 – 3.04 (m, 2H, CH2NH 
LINKER), 2.08 – 2.01 (m, 3H, NHCOCH3), 2.01 – 1.87 (m, 2H, CH2 LINKER). 
 
31P NMR (162 MHz, D2O) δ (ppm): - 0.94. 
 
13C NMR (101 MHz, D2O) δ 93.69, 93.63 (C-1), 72.95 (C-3), 70.14 (C-5), 69.45 (C-4), 63.26, 63.20 
(CH2O LINKER), 60.25 (C-6), 53.70, 53.62 (C-2), 36.93 (CH2NH LINKER), 27.65 (CH2 LINKER), 21.74 
(NHCOCH3). 
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1H (400 MHz, D2O): 
 
31P NMR (162 MHz, D2O): 
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HETCOR 31P-1H (400 MHz, D2O): 
 
13C – DEPT135 (101 MHz, D2O): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(4-O-Acetyl-2-azido-3,6-di-O-
benzyl-2-deoxy-α-D-glucopyranosyl phosphate) (22), triethylammonium 
salt  
 
Synthetic procedure 
H-phosphonate 18 (76.4 mg, 0.13 mmol, 1 eq) and 3-N-Cbz-propanolamine (136 mg, 0.65 mmol, 5 
eq) are first co-evaporated three times with dry pyridine, thereafter they are dried by high vacuum 
pump overnight. The reactants were dissolved in dry pyridine (1.3 mL), then pivaloyl chloride (40 
µL, 0.325 mmol, 2.5 eq) was added dropwise at 0°C and the reaction mixture was stirred under 
nitrogen at r.t.. The reaction completion was monitored by HPTLC (DCM:MeOH 9:1). After cooling 
to -40°C, a freshly prepared 0.5 M solution of iodine (2.5 eq) in pyridine/water 19:1 (2 mL) was 
added. The oxidation was completed at 0°C and quenched by dropwise addition of a 0.5 M 
solution of Na2S2O3 · 5H2O  (10% w/v, 10 mL). The mixture was diluted with DCM (50 mL), washed 
with Na2S2O3 · 5H2O (0.5 M, 2x50 mL), then with cold TEAB (0.5 M, 1x25 mL), dried (Na2SO4), 
filtered and concentrated. The crude was purified by flash chromatography (DCM:MeOH + 1% 
TEA). The phosphate bridge has to be stabilized, washing with 0.25M cold TEAB [then drying 
(Na2SO4), filtering and concentrating] the purified product. Product 22 (66.3 mg, 0.083 mmol, 64% 
yield) was obtained as pure-α anomer. 
Product characterization 
Formula C39H54N5O11P 
Molecular Weight 799.80 g/mol 
HP-TLC conditions Rf (DCM/MeOH 9:1) 0.30 
 Rf (DCM/MeOH 8:2) 0.60 
Optical rotation 
25
D
+ 35.76 (c = 1.2 in CHCl3) 
HRMS (ESI negative)  
Experimental m/z: 697.22780 [M]- 
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NMR 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.17 (m, 15H, Ar), 6.20 (t, J = 5.5 Hz, 1H, NH), 5.62 (dd, JH-1,P 
=7.8, JH-1,H-2 = 3.1 Hz, 1H, H-1), 5.06 (t, JH-4,H-3 = JH-4,H-5 = 9.7 Hz, 1H, H-4), 5.02 (s, 2H, CH2Ph), 4.74 
(d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.56 (d, J = 11.1 Hz, 1H, ½ CH2Ph), 4.41 (q, J = 11.8 Hz, 2H, CH2Ph), 
4.20 – 4.09 (m, 1H, H-5), 4.05 – 3.90 (m, 3H, H-3, CH2O LINKER), 3.56 – 3.46 (m, 3H, H-2, H-6, H-6’), 
3.27 (dd, J = 11.5, 5.7 Hz, 2H, CH2NH LINKER), 1.81 (s, 3H, CH3CO), 1.73 – 1.55 (m, 2H, CH2 LINKER). 
 
31P NMR (162 MHz, CDCl3) δ -0.52. 
 
13C NMR (101 MHz, CDCl3) δ 169.67, 156.60 (CO), 137.70, 136.97(Cq Ar), 128.47, 128.43, 128.29, 
128.15, 128.02, 127.98, 127.94, 127.84, 127.69 (CH Ar), 93.76, 93.71 (C-1), 77.73 (C-3), 74.70 
(CH2Ph), 73.48 (CH2Ph), 70.88 (C-4), 69.90 (C-5), 69.05 (C-6), 66.30 (CH2Ph), 63.69, 63.61 (C-2),  
62.80 (CH2O LINKER), 37.28 (CH2NH LINKER), 30.21, 30.15 (CH2 LINKER), 20.79 (CH3CO). 
 
 
 
 
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
 
HETCOR 1H-13C (400 MHz, CDCl3): 
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13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(2-Azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate) (23), triethylammonium salt 
 
Synthetic procedure 
Compound 22 (60.3 mg, 0.075 mmol) was treated as described in the General Procedure C. 
Product 23 (55.32 mg, 0.073 mmol) was obtained in quantitative yield. 
Product characterization 
Formula C37H52N5O10P 
Molecular Weight 757.80 g/mol 
HP-TLC conditions Rf (DCM/MeOH 85:15) 0.29 
Optical rotation 
25
D
+ 18.50 (c = 1.1 in CHCl3) 
MS (ESI) 
Experimental m/z: 655.2 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.44 – 7.20 (m, 15H, Ar), 6.17 (t, J = 5.7 Hz, 1H, NHCbz), 5.63 (dd, JH-1,P 
= 7.7, JH-1,H-2 = 3.3 Hz, 1H, H-1), 5.05 (s, 2H, CH2Ph), 4.86 (s, 2H, CH2Ph), 4.51 (q, J = 12.0 Hz, 2H, 
CH2Ph), 4.13 – 4.04 (m, 1H, H-5), 3.98 (dt, J = 7.4, 5.8 Hz, 2H, CH2O LINKER), 3.93 – 3.83 (t, JH-3,H-2 = JH-
3,H-4 = 10.1, 1H, H-3), 3.76 – 3.59 (m, 3H, H-4, H-6, H-6’), 3.39 (ddd, JH-2,H-3 = 10.1, JH-2,H-1 = 3.2, JH-2,P 
= 2.2 Hz, 1H, H-2), 3.31 (dd, J = 11.9, 6.0 Hz, 2H, CH2NH LINKER), 1.76 – 1.63 (m, 2H, CH2 LINKER). 
 
31P NMR (162 MHz, CDCl3) δ -0.61. 
 
13C NMR (101 MHz, CDCl3) δ 156.70 (CO), 138.49, 137.98, 137.15 (Cq Ar), 128.58, 128.50, 128.48, 
128.19, 127.99, 127.92, 127.83 (CH Ar), 94.20, 94.15 (C-1), 79.81 (C-3), 75.02 (CH2Ph), 73.70 
(CH2Ph), 72.61 (C-4), 71.21 (C-5), 70.25 (C-6), 66.42 (CH2Ph), 63.71, 63.63 (C-2), 62.99, 62.93 (CH2O 
LINKER), 37.50 (CH2NH LINKER), 29.78 (CH2 LINKER). 
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1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
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13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-[2-Azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate 4-(2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate)] (24), 
triethylammonium salt 
 
Synthetic procedure 
H-phosphonate donor 17 (123.4 mg, 0.23 mmol, 1 eq) was coupled with acceptor 23 (202.6 mg, 
0.27 mmol, 1.2 eq) as described in the General Procedure E. Dimer 24 (94.7 mg, 0.073 mmol) was 
obtained in 27% yield. 
Product characterization 
Formula C63H87N9O17P2 
Molecular Weight 1304.40 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.36 
Optical rotation 
25
D
+ 12.76 (c = 1.15 in CHCl3) 
HRMS (ESI) 
Experimental m/z (%): 1122.30177 [M+Na]- 
 549.65634 [M]2- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.58 – 7.41 (m, 5H, Ar), 7.41 – 7.13 (m, 20H, Ar), 6.34 (t, J = 5.9 Hz, 1H, 
NHCbz), 5.78 – 5.67 (m, 2H, H-1 A, H-1 B), 5.56 (s, 1H, CHPh), 5.34 (d, J = 11.0 Hz, 1H, ½ CH2Ph), 
5.06 (s, J = 1.4 Hz, 2H, CH2Ph), 4.80 (t, 2H, 2x ½CH2Ph), 4.61 (dt, 3H, ½CH2Ph, CH2Ph), 4.42 (dd, JH-
4A,H-3A = 19.2,  JH-4A,H-5A =  10.0 Hz, 1H, H-4A), 4.34 – 4.16 (m, 3H, H-6B, H-5A,H-5B), 4.13 – 3.93 (m, 
5H, H-6A, H-3B, H-3A, CH2O LINKER), 3.87 (dd,  JH-6’A,H-5A =  10.9,  JH-6’A,H-6A =  6.2 Hz, 1H, H-6’A), 3.77 – 
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3.65 (m, 2H, H-6’B, H-4B), 3.52 – 3.35 (m, 2H, H-2A, H-2B), 3.30 (dd, J = 10.9, 5.2 Hz, 2H, CH2NH 
LINKER), 1.69 – 1.52 (m, 2H, CH2 LINKER). 
31P NMR (162 MHz, CDCl3) δ -0.23, -1.99.    
 
13C NMR (101 MHz, CDCl3) δ 139.22, 138.93, 138.09, 137.50 (Cq Ar), 128.90, 128.36, 128.28, 
128.15, 128.08, 128.03, 128.01, 127.80, 127.72, 127.66, 127.18, 127.13, 126.17 (CH Ar), 101.48 
(CHPh), 94.56, 94.50 (C-1B), 93.80, 93.74 (C-1A), 82.83 (C-4B), 79.05, 79.02 (C-3B), 76.53 (C-3A), 
74.79 (CH2Ph), 74.74 (C-4A), 74.36 (CH2Ph), 73.36 (CH2Ph), 72.22, 72.19 (C-5A), 69.87 (C-6A), 68.97 
(C-6B), 66.19 (CH2 Cbz), 64.00, 63.92 (C-2B), 63.71, 63.62 (C-2A), 63.29 (C-5B), 62.74, 62.68 (CH2O 
LINKER), 37.25 (CH2NH LINKER), 30.17 (CH2 LINKER). 
 
 
 
 
 
 
 
 
 
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-[2-Acetamido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate 4-(2-acetamido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate)] (25), 
triethylammonium salt 
 
Synthetic procedure 
Dimer 24 (94.7 mg, 0.073 mmol) was converted into the corresponding acetamide 25 (34.7 mg, 
0.026 mmol, 36% yield) as described in the General Procedure F. The phosphate bridge has to be 
stabilized, washing with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the 
purified product. 
Product characterization 
Formula C67H95N5O19P2 
Molecular Weight 1336.4 g/mol 
TLC conditions Rf (DCM/MeOH 7:3) 0.41 
Optical rotation 
25
D
+ 22.03 (c = 0.3 in MeOH) 
MS (ESI) 
Experimental m/z (%): 1132.4 (100) [M]- 
 1154.5 (70) [M+Na]- 
 
Fully NMR characterization of product 25 wasn’t possible. 
The NMR analysis has been conducted in different solvent (CDCl3, CD3OD, and (CD3)2S) and 
temperature conditions. 
The spectra reported below are the best for resolution, and correspond to 1H, 31P and HETCOR in 
(CD3)2SO at +60°C.  
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1H (400 MHz, (CD3)2SO): 
 
31P NMR (162 MHz, (CD3)2SO): 
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HETCOR 1H-13C (400 MHz, (CD3)2SO): 
  
anomerics 
CH benzylidene acetal 
CH2 Ph 
NHCH2 LINKER 
CH2 LINKER 
OCH2 LINKER 
2x H-2 
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3-aminopropyl 1-O-[2-Acetamido-2-deoxy-α-D-glucopyranosyl 
phosphate 4-(2-Acetamido-2-deoxy-α-D-glucopyranosyl phosphate)] 
(26), disodium salt  
 
Synthetic procedure 
Fully protected dimer 25 (13 mg, 0.017 mmol) was submitted to hydrogenation as described in the 
General Procedure G. Final dimer 26 (6.5 mg, 0.016 mmol, 62% yield) was obtained as disodium 
salt after ion exchange (see General Procedure H). 
Product characterization 
Formula C19H35N3Na2O17P2 
Molecular Weight 685.4 g/mol 
Optical rotation 
25
D
+ 19.00 (c = 0.07 in H2O) 
HRMS (ESI) 
Experimental m/z: 661.77595 [M+Na]- 
NMR 
1H NMR (400 MHz, H2O+D2O) δ 5.17 (d, J = 3.3 Hz, 1H), 4.70 (dt, J = 8.2, 3.5 Hz, 1H), 4.12 – 4.05 (m, 
1H), 3.97 – 3.29 (m, 20H), 3.13 (s, 1H), 2.05 – 1.89 (m, 7H), 1.30 (d, J = 6.9 Hz, 2H). 
 
31P NMR (162 MHz, CDCl3) δ: +3.92, +0.90. 
 
13C NMR (101 MHz, D2O) δ 94.83, 94.77, 90.68 (C-1B), 90.41 (C-1A), 75.79 (C-3A), 73.74 (C-3B), 
71.40, 70.51 (C-5B), 70.36 (C-4B), 69.89, 69.66 (C-4A), 68.34 (CH2O LINKER), 60.40 (C-6A, C-6B), 
56.52, 56.26 (C-2B), 53.93, 53.88 (C-2A), 22.02 (NHCOCH3), 21.74 (CH2NH LINKER), 19.91 (CH2 LINKER). 
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1H (400 MHz, D2O): 
 
31P NMR (162 MHz, D2O): 
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13C – DEPT135 (101 MHz, D2O): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-[2-Azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate 4-(4-O-Acetyl-2-azido-3,6-di-O-
benzyl-2-deoxy-α-D-glucopyranosyl phosphate)] (27), bis-
triethylammonium salt  
 
Synthetic procedure 
H-phosphonate 18 (366 mg, 0.62 mmol, 1.1 eq) and acceptor 23 (425.5 mg, 0.56 mmol, 1 eq) are 
first co-evaporated three times with dry pyridine, thereafter they are dried by high vacuum pump 
overnight. The reactants were dissolved in dry pyridine (2.5 mL), then pivaloyl chloride (140 µL, 
1.11 mmol, 1.5 eq) was added dropwise at 0°C and the reaction mixture was stirred under 
nitrogen at r.t. for half an hour. The reaction completion was monitored by HPTLC (DCM:MeOH 
85:15). After cooling to -40°C, a freshly prepared 0.5 M solution of iodine (470 mg, 1.85 mmol, 2.5 
eq) in pyridine/water 19:1 (2 mL) was added. The oxidation was completed at 0°C (10 min) and 
quenched by dropwise addition of a 0.5 M solution of Na2S2O3 · 5H2O  (10% w/v, 10 mL). The 
mixture was diluted with DCM (50 mL), washed two times with Na2S2O3 · 5H2O (0.5 M, 2x50 mL), 
then with cold TEAB (0.5 M, 1x25 mL), dried (Na2SO4), filtered and concentrated. The crude was 
purified by flash chromatography (DCM:MeOH + 1% TEA). The phosphate bridge has to be 
stabilized, washing with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the 
purified product 22 (145 mg, 0.11 mmol, 20% yield). 
Product characterization 
Formula C65H91N9O18P2 
Molecular Weight 1348.4 g/mol 
HP-TLC conditions Rf (DCM/MeOH 85:15) 0.26 
Fully spectroscopic characterization of product 27 is currently in progress. 
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1H (400 MHz, CDCl3):
 
31P NMR (162 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-[(2-azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate) 4-(2-azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate)] (28), bis-triethylammonium salt 
 
Synthetic procedure 
Compound 27 (145 mg, 0.11 mmol) was treated as described in the General Procedure C. Product 
28 (114 mg, 0.08 mmol) was obtained in 80% yield as crude. 
Product characterization 
Formula C63H89N9O17P2 
Molecular Weight 1306.4 g/mol 
HP-TLC conditions Rf (DCM/MeOH 85:15) 0.26 
Fully spectroscopic characterization of product 28 is currently in progress. 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-{2-Azido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate 4-[2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate 4-(2-azido-3,6-di-O-
benzyl-2-deoxy-α-D-glucopyranosyl phosphate)]} (29), tris-
triethylammonium salt 
 
Synthetic procedure 
H-phosphonate donor 17 (71 mg, 0.12 mmol, 1.5 eq) was coupled with acceptor 28 (114 mg, 0.08 
mmol, 1 eq) as described in the General Procedure E. Trimer 29 (95 mg, 0.051 mmol) was 
obtained in 43% yield. 
Product characterization 
Formula C89H124N7O27P3 
Molecular Weight 1851.9 g/mol 
HP-TLC conditions Rf (DCM/MeOH 8:2) 0.19 
Optical rotation 
25
D
+ 12.81 (c = 1 in CHCl3) 
HRMS (ESI) 
Experimental m/z (%): 773.21635 [M]2- 
 784.20616 [M+Na]2- 
 1591.39910 [M+2Na]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.59 – 7.04 (m, 35H, Ar), 6.32 (s, 1H, NHCbz), 5.78 (dd, JH-1A,P = 7.0, JH-
1A,H-2A =2.4 Hz, 1H, H-1A), 5.74 – 5.58 (m, 2H, H-1B, H-1C), 5.52 (s, 1H, CHPh), 5.41 – 5.16 (m, 2H, 
2x ½ CH2Ph), 5.03 (s, 2H, CH2Ph), 4.83 – 4.70 (m, 2H, 2x ½ CH2Ph), 4.68 – 4.52 (m, 5H, 3X ½ CH2Ph, 
CH2Ph), 4.52 – 4.32 (m, 2H, H-4B, H-4A), 4.32 – 3.76 (m, 12H, H-6C, H-5A, H-5B, H-6A, H-3B, H-3A, 
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H-6B, H-3C, CH2O LINKER, H-6’A, H-6’B), 3.76 – 3.53 (m, 3H, H-6’C, H-4C), 3.40 (d, J = 9.6 Hz, 3H, H-
2A, H-2B, H-2C), 3.25 (d, J = 5.2 Hz, 2H, CH2NH LINKER), 1.62 – 1.45 (m, 2H, CH2 LINKER). 
31P NMR (162 MHz, CDCl3) δ -0.30 (s, 1P, A), -2.26 (s, 2P, B, C). 
 
13C NMR (101 MHz, CDCl3) δ 128.45, 128.38, 128.25, 128.23, 128.16, 128.10, 128.05, 127.95, 
127.91, 127.74, 127.20, 127.14, 126.27, 126.24 (CH Ar), 101.56 (CH Ph), 94.61, 94.56 (C-1C), 94.08, 
94.02, 93.89, 93.84 (C-1A, C-1B), 82.90 (C-4C), 79.46, 79.00 (C-3A, C-3B), 76.68 (C-3C), 75.11, 75.05 
(C-4A), 74.86 (CH2 Ph), 74.77, 74.71 (C-4B), 74.51 (CH2 Ph), 73.52, 73.42 (CH2 Ph), 72.29 (C-5A), 
72.27 (C-5B), 70.04 (C-6B), 69.70 (C-6A), 69.05 (C-6C), 66.27 (CH2 Ph), 64.11, 64.03 (C-2A, C-2B), 
63.80, 63.71 (C-2C), 63.35 (C-5C), 62.79 (CH2O LINKER), 37.33 (CH2NH LINKER), 29.78 (CH2 LINKER). 
 
 
 
 
 
 
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-{2-Acetamido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate 4-[2-acetamido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl phosphate 4-(2-acetamido-
3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl phosphate)]} (30), tris-
triethylammonium salt 
 
Synthetic procedure 
Trimer 29 (80 mg, 0.043 mmol) was converted into the corresponding acetamide 30 (22.14 mg, 
0.011 mmol, 25% yield) as described in the General Procedure F.  
Product characterization 
Formula C95H136N7O27P3 
Molecular Weight 1901.1 g/mol 
HP-TLC conditions Rf (DCM/MeOH 7:3) 0.27 
HRMS (ESI negative) 
Experimental m/z (%): 1639.47585 [M+2Na]- 
 808.24062 [M+Na]2- 
 531.16428 [M]3- 
 
Fully NMR characterization of product 30 wasn’t possible. 
The NMR analysis has been conducted in different solvent (CDCl3, and CD3OD) and temperature 
conditions. 
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3-aminopropyl 1-O-{2-Acetamido-2-deoxy-α-D-glucopyranosyl 
phosphate 4-[2-acetamido-2-deoxy-α-D-glucopyranosyl phosphate 4-(2-
acetamido-2-deoxy-α-D-glucopyranosyl phosphate)]} (31), tris-sodium 
salt 
 
Synthetic procedure 
Fully protected trimer 30 (20 mg, 0.010 mmol) was submitted to hydrogenation as described in 
the General Procedure G. Final trimer 31 (8.6 mg, 0.009 mmol, 87% yield) was obtained as 
disodium salt after ion exchange (see General Procedure H). 
Product characterization 
Formula C26H48N4Na3O25P3 
Molecular Weight 990.6 g/mol 
Optical rotation 
25
D
+ 86.61 (c = 0.4 in H2O) 
HRMS (ESI) 
Experimental m/z: 967.16133 [M+2Na]- 
 945.17800 [M+H+Na]- 
 472.08681 [M+Na]2- 
 461.09538 [M+H]2- 
NMR 
1H NMR (400 MHz, D2O) δ 5.55 – 5.45 (m, 2H, H-1A, H-1B), 5.45 – 5.35 (m, 1H, H-1C), 4.16 – 3.61 
(m, 16H, CH2O LINKER, 3x H-2 ABC, 3x H-6 ABC, 3x H-6’ ABC, 3x H-3 ABC,3x  H-5 ABC, 2x H-4 AB), 3.51 
(t, JH-4,H-3 = JH-4,H-5 = 9.5 Hz, 1H, H-4C), 3.10 (t, J = 7.0 Hz, 1H, CH2NH LINKER), 2.07 – 1.88 (m, 11H, 
NHCOCH3, CH2 LINKER). 
31P NMR (162 MHz, D2O) δ (ppm): - 0.31, -0.65, -0.71. 
13C NMR (101 MHz, D2O) δ 174.61 (CO), 94.54, 94.49 (C-1B), 94.25, 94.18 (C-1C), 93.60, 93.55 8 (C-
1), 74.04 (2x C-3 AB), 73.08 (C-3C), 72.20 (2x C-5 AB), 70.87 (C-5C), 70.14, 69.58 (C-4C), 63.41 
(CH2O LINKER), 60.35 (3x C-6), 53.74 (3x C-2), 37.17 (CH2NH LINKER), 27.69 (CH2 LINKER), 22.16 
(NHCOCH3). 
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1H (400 MHz, D2O): 
 
31P NMR (162 MHz, D2O): 
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13C – DEPT135 (101 MHz, D2O): 
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Monomer-Glycoconjugate(CRM197) (33) 
 
Synthetic procedure 
reagents M.W. (g/mol) d (g/cm3) mmol amount eq 
20 380.26 - 0.015 5.65 mg 1 
disuccinimidyl adipate 340.29 - 0.15 51 mg 10 
triethylamine 101.19 0.726 0.3 42 L 20 
DMSO 78.13 1.1 11.26 800 L - 
Monomer 20 (15 mol), dissolved in 200 L of DMSO containing triethylamine (20 eq), was slowly 
dropped into a murky mixture of disuccinimidyl adipate (10 eq) in DMSO (400 L). After 2.5 hours 
of vigorous stirring the activated oligosaccharide was purified from the excess of linker by 
precipitation of the reaction mixture in nine volumes (9 mL) of ethyl acetate. The pellet obtained 
by subsequent centrifugation was washed 10 times with 3 mL (1/3 of the volume) of ethyl acetate 
and then dried under vacuum (4 hours of lyophilisation). 
Compound 32 (5.35 mg) was reacted with 2.5 mg of CRM197 (77 L of a solution 32.5mg/mL of 
protein in NaPi 10 mM +10% saccharosium, pH 7.2) in 77 L of 100 mM NaPi buffer (pH 7.2): the 
conjugation stoichiometry was about 100:1 sugar/protein (mol/mol). The mixture was incubated 
over night at room temperature, mixing very gently with a magnetic stirrer. The glycoconjugate 
was purified from the excess of unconjugated carbohydrate using precipitation by (NH4)2SO4. 
Product characterization 
MALDI-TOF mass spectrum of 33 was recorded (Figure 3): the found value for the glycoconjugate 
33 was 61523.32 m/z, corresponding to approximately 5 oligosaccharide chains per CRM197 
molecule. 
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Figure 3 
We made a second attempt of glycoconjugation: the pellet 32 (1.95 mg) was reacted, with a 
conjugation stoichiometry of 150:1 sugar/protein (mol/mol), with CRM197 (1.3 mg, 40 L) in 100 
M NaPi buffer pH 7.2 (10 L). After 6 hours the glycoconjugate was analysed by SDS-PAGE in 4-
12% Bis-Tris Gel. The mixture was incubated over night at room temperature, mixing very gently 
with a magnetic stirrer. CRM197 glycoconjugate was analysed by SDS-PAGE in 4-12% Bis-Tris Gel 
(Figure 4), and MALDI-TOF mass spectrum was recorded (Figure 5): the found value for the 
glycoconjugate MG(CRM)_02 was 62258.89 m/z, corresponding to approximately 7 
oligosaccharide chains per CRM197 molecule. 
The glycoconjugate was not purified and left in the freezer (-20°C). 
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Figure 4 
 
Figure 5  
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Dimer-Glycoconjugate(CRM197) (35) 
 
Synthetic procedure 
reagents M.W. (g/mol) d (g/cm3) mmol amount eq 
26 685.42 - 0.008 5.5 mg 1 
disuccinimidyl adipate 340.29 - 0.08 28 mg 10 
triethylamine 101.19 0.726 0.16 20 L 20 
DMSO 78.13 1.1 8.45 600 L - 
Dimer 26 (8 mol), dissolved in 200 L of DMSO containing triethylamine (20 eq), was slowly 
dropped into a murky mixture of disuccinimidyl adipate (10 eq) in DMSO (200 L). After 3 hours of 
vigorous stirring the activated oligosaccharide was purified from the excess of linker by 
precipitation of the reaction mixture in nine volumes (9 mL) of ethyl acetate. The pellet obtained 
by subsequent centrifugation was washed 10 times with 3 mL (1/3 of the volume) of ethyl acetate 
and then dried under vacuum (lyophilisation over night). We failed to determine the active ester 
groups. 
Compound 34 (4 mg) was reacted with 2.5 mg of CRM197 (76 L of a solution 32.5mg/mL of 
protein in 10 mM NaPi buffer +10% saccharosium, pH 7.2) in 76 L of 100 mM NaPi buffer (pH 
7.2): the conjugation stoichiometry was about 100:1 sugar/protein (mol/mol). The mixture was 
incubated over night at room temperature, mixing very gently with a magnetic stirrer. The 
glycoconjugate 35 was purified from the excess of unconjugated carbohydrates using precipitation 
by (NH4)2SO4.  
Product characterization 
35 was analysed by SDS-PAGE in 4-12% Bis-Tris Gel (Figure 6), and MALDI-TOF mass spectrum was 
recorded (Figure 7): the profile of the glycoconjugate 35 was composed of a polydispersion 
centered at 61731.51 m/z, corresponding to approximately 4 oligosaccharide chains per CRM197 
molecule. 
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Figure 6 
 
Figure 7  
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Monomer-Glycoconjugate(HSA) (37) 
 
Synthetic procedure 
reagents M.W. (g/mol) d (g/cm3) mmol amount eq 
20 380.26 - 0.008 3.1 mg 1 
bis(succinimidyl) 
penta(ethylene glycol) 
535.5 - 0.08 
42.84 mg 
425 L 
of a 100mg/mL 
solution 
10 
triethylamine 101.19 0.726 0.16 23 L 20 
DMSO 78.13 1.1 11.61 400 L - 
Monomer 20 (8 mol), dissolved in 200 L of DMSO containing triethylamine (20 eq), was slowly 
dropped into a solution of BS(PEG)5 (10 eq) in DMSO. After 3 hours of vigorous stirring the 
activated oligosaccharide was purified from the excess of linker by precipitation of the reaction 
mixture in nine volumes (9 mL) of acetone. The pellet obtained by subsequent centrifugation was 
washed 10 times with 3 mL (1/3 of the volume) of acetone and then dried under vacuum (4 hours 
of lyophilisation). Compound 36 (1.95 mg) was reacted with HSA (1.3 mg, 40 L) in 100 M NaPi 
buffer pH 7.2 (10 L), with a conjugation stoichiometry of 150:1 sugar/protein (mol/mol). 
Product characterization 
After 6 hours of incubation, mixing very gently with a magnetic stirrer, the glycoconjugate 37 was 
analysed by SDS-PAGE in 4-12% Bis-Tris Gel (Figure 8) and MALDI-TOF mass spectrum was 
recorded (Figure 9): the found value for 37 was 68320.268 m/z, corresponding to approximately 3 
oligosaccharide chains per HSA molecule. The glycoconjugate was stored at -20°C for future 
purification. 
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Figure 8 
 
Figure 9 
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Dimer-Glycoconjugate(HSA) (39) 
 
Synthetic procedure 
reagents M.W. (g/mol) d (g/cm3) mmol amount eq 
26 685.42 - 0.0047 3.23 mg 1 
bis(succinimidyl) 
penta(ethylene glycol) 
535.5 - 0.047 
(25.17 mg) 
250 L 
of a 100mg/mL 
solution  
10 
triethylamine 101.19 0.726 0.094 17 L 20 
DMSO 78.13 1.1 11.61 300 L - 
Dimer 26 (4.7 mol), dissolved in 150 L of DMSO containing triethylamine (20 eq), was slowly 
dropped into a solution of BS(PEG)5 (10 eq) in DMSO. After 3 hours of vigorous stirring the 
activated oligosaccharide was purified from the excess of linker by precipitation of the reaction 
mixture in nine volumes (9 mL) of acetone. The pellet obtained by subsequent centrifugation was 
washed 10 times with 3 mL (1/3 of the volume) of acetone and then dried under vacuum (4 hours 
of lyophilisation). Compound 38 (1.71 mg) was reacted with CRM197 (1 mg, 33 L) in 100 M NaPi 
buffer pH 7.2 (33 L), with a conjugation stoichiometry of 100:1 sugar/protein (mol/mol). The 
mixture was incubated over night at room temperature, mixing very gently with a magnetic 
stirrer. 
Product characterization 
CRM197 glycoconjugate was analysed by SDS-PAGE in 4-12% Bis-Tris Gel (Figure 10), and MALDI-
TOF mass spectrum was recorded (Figure 11). Both the characterizations highlighted the lack of 
conjugation: the found value for 39 corresponded to just 1 oligosaccharide chain per HSA 
molecule. 
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Figure 10 
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Thexyldimethylsilyl 2-Acetamido-3-O-benzyl-4,6-O-benzylidene- 
2-deoxy-β-D-glucopyranoside (40) 
 
Synthetic procedure 
Compound 1 (1.4 g, 2.7 mmol) was treated as described in the General Procedure F. Product 40 is 
obtained in quantitative yield (1.45 g, 2.6 mmol). 
Product characterization 
Formula C30H43NO6Si 
Molecular Weight 541.75 g/mol 
TLC conditions Rf (H/EA 9:1) 0.13 
Optical rotation 
25
D
- 44.28 (c = 1 in MeOH) 
HRMS (ESI positive) 
m/z (%): 541.9 (20) [M]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.53 – 7.23 (m, Ar), 5.56 (s, 1H, CHPh), 5.44 (d, J = 7.7 Hz, 1H, NH), 
5.18 (d, J1,2 = 7.8 Hz, 1H, H-1), 4.89 (d, J = 11.8 Hz, 1H, ½ CH2Ph), 4.64 (d, J = 11.9 Hz, 1H, ½ CH2Ph), 
4.57 (s, 2H, CH2Ph), 4.33 – 4.24 (m, 2H, H-6, H-3), 3.78 (t, J6’,6 = J6’,5 = 10.3 Hz, 1H, H-6’), 3.69 (t, J4,3 
= J4,5 = 9.2 Hz, 1H, H-4), 3.60 – 3.45 (m, 1H, H-5), 3.23 (dt, J2,3 = 10.1, J2,1 = 7.8 Hz, 1H, H-2), 1.86 (s, 
3H, CH3CO), 1.71 – 1.50 (m, 1H, CH TDS), 0.88 – 0.85 (m, 3H, CH3 TDS), 0.83 (s, 2H), 0.14 (s, J = 3.2 
Hz, 1H), 0.11 (s, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 170.14 (CO), 137.67, 137.64 (Cq Ar), 129.08, 128.55, 128.49, 128.40, 
127.93, 127.85, 127.77, 126.24 (CH Ar), 101.39 (CHPh), 95.46 (C-1), 83.08 (C-4), 76.51(C-3), 74.50 
(CH2Ph), 72.29 (CH2Ph), 69.06 (C-6), 66.15 (C-5), 60.31 (C-2), 34.22 (CH TDS), 24.96 (Cq TDS), 23.75 
(CH3CO), 20.18, 18.68 (CH3 TDS), -1.07, -2.29 (CH3Si TDS). 
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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Thexyldimethylsilyl 2-Acetamido-4-O-acetyl-3,6-di-O-benzyl- 
2-deoxy-β-D-glucopyranoside (41) 
 
Synthetic procedure 
Compound 2 (1.69 g, 2.98 mmol) was treated as described in the General Procedure F. Product 41 
was obtained in quantitative yield (1.7 g, 2.9 mmol). 
Product characterization 
Formula C32H47NO7Si 
Molecular Weight 585.80 g/mol 
TLC conditions Rf (H/EA 9:1) 0.18 
Optical rotation 
25
D
- 2.92 (c = 1.3 in MeOH) 
MS (ESI positive) 
m/z (%): 608.5 (100) [M+Na]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ(ppm): 7.37 – 7.20 (m, 10H, Ar), 5.60 (s, 1H, NH), 5.19 (d, J1,2 = 7.8 Hz, 
1H, H-1), 4.99 (t, J4,5 = J4,3 = 9.5 Hz, 1H, H-4), 4.59 (q, J = 11.5 Hz, 2H, CH2Ph), 4.52 (s, 2H, CH2Ph), 
4.33 (dd, J3,2 = 10.3, J3,4 = 9.5 Hz, 1H, H-3), 3.70 – 3.62 (m, 1H, H-5), 3.54 (d, J = 4.5 Hz, 2H, H-6, H-
6’), 3.18 (dt, J2,3 = 10.3, J1,2 = 7.8 Hz, 1H, H-2), 1.88 (s, 3H, CH3CO), 1.87 (s, 3H, CH3CO), 1.62 (ept, J 
= 7.0 Hz, 1H, CH TDS), 0.87 (d, J = 1.8 Hz, 3H, CH3 TDS), 0.86 (d, J = 1.7 Hz, 3H, CH3 TDS), 0.84 (d, J = 
2.2 Hz, 6H, 2 CH3 TDS), 0.17 (s, 3H, CH3Si TDS), 0.13 (s, 3H, CH3Si TDS). 
 
13C NMR (101 MHz, CDCl3) δ(ppm): 170.63, 169.99 (CO), 138.49, 138.27 (Cq Ar), 128.89, 128.76, 
128.57, 128.45, 128.03, 127.82, 127.70 (CH Ar), 94.58 (C-1), 78.00 (C-3), 73.87 (CH2Ph), 73.65 
(CH2Ph), 73.37 (C-5), 72.21 (C-4), 70.16 (C-6), 60.21 (C-2), 34.23 (CH TDS), 24.96 (Cq TDS), 23.63 
(CH3CO), 21.04, 20.22 , 18.69 (CH3 TDS), -1.71, -3.39 (CH3Si TDS). 
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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2-Acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-
glucopyranose (42) 
 
Synthetic procedure 
Compound 40 (1.4 g, 2.7 mmol) was treated as described in the General Procedure A; but without 
the addition of AcOH. Product 42 was obtained in 85% yield (540 mg, 2.6 mmol). 
Product characterization 
Formula C22H25NO6 
Molecular Weight 339.44 g/mol 
TLC conditions Rf (H/EA 1:1) 0.10 
 The spectroscopic data were in agreement with those reported in literature.21 
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2-Acetamido-4-O-acetyl-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranose 
(43) 
 
Synthetic procedure 
Compound 41 (1.3 g, 2.2 mmol) was treated as described in the General Procedure A; but without 
the addition of AcOH. Product 43 is obtained in 81% yield (789.5 mg, 2.6 mmol). 
Product characterization 
Formula C24H29NO7 
Molecular Weight 443.49 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.49 
Optical rotation 
25
D
+ 38.46 (c = 1.1 in MeOH) 
MS (ESI positive) 
m/z (%): 466.4 (100) [M+Na]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ(ppm): 7.36 – 7.23 (m, 10H, Ar), 5.49 (d, J = 8.7 Hz, 1H, NH), 5.23 (d, J1,2 
= 3.5 Hz, 1H, H-1), 5.07 (t, J4,5 = J4,3 = 9.5 Hz, 1H, H-4), 4.63 (d, J = 11.5 Hz, 1H, ½ CH2Ph), 4.52 (d, J = 
11.5 Hz, 1H, ½ CH2Ph), 4.51 (s, 2H, CH2Ph), 4.23 – 4.05 (m, 2H, H-2, H-5), 3.86 (dd, J3,2 = 10.5, J3,4 = 
9.5 Hz, 1H, H-3), 3.53 – 3.45 (m, 2H, H-6, H-6’), 1.94 (s, 3H, CH3CO), 1.85 (s, 3H, CH3CO). 
 
13C NMR (101 MHz, CDCl3) δ 170.52, 169.75 (CO), 138.18, 137.81 (Cq Ar), 128.66, 128.51, 128.24, 
128.18, 128.14, 128.04, 127.91 (CH Ar), 92.04 (C-1), 76.84 (C-3), 73.70 (CH2Ph), 73.02 (CH2Ph), 
71.23 (C-4), 69.60 (C-6), 69.56 (C-5), 52.96 (C-2), 23.45 (CH3CO), 21.02 (CH3CO). 
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
  
NHAc                   H-1 α 
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2-Acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-D-glucopyranosyl 
Hydrogen-phosphonate, triethylammonium salt (44), α/β mixture 
 
Synthetic procedure 
Salicylchlorophosphite (146 mg, 0.72 mmol) was slowly added to a solution of the alcohol 42 (192 
mg, 0.48 mmol) in dry pyridine (1.9 mL) at 0°C. The reaction was stirred at r.t. for 4 hours. Then a 
1M solution of TEAB (4 mL/mmol) was added to the reaction at r.t., and the mixture was diluted 
with CH2Cl2, washed three times with cold TEAB (0.5 M), dried (Na2SO4), filtered and concentrated. 
The crude was purified by flash chromatography. The H-phosphonate has to be stabilized, washing 
with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the purified product 44 
(144 mg, 0.255 mmol, 75% yield). 
Product characterization 
Formula C28H41N2O8P 
Molecular Weight 564.61 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.12 
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2-Acetamido-4-O-acetyl-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl 
Hydrogen-phosphonate, triethylammonium salt (45) 
 
Synthetic procedure 
Salicylchlorophosphite (96 mg, 0.473 mmol) was slowly added to a solution of the alcohol 43 (140 
mg, 0.315 mmol) in dry pyridine (1 mL) at 0°C. The reaction was stirred at r.t. for 3.5 hours. Then a 
1M solution of TEAB (4 mL/mmol) was added to the reaction at r.t., and the mixture was diluted 
with CH2Cl2, washed three times with cold TEAB (0.5 M), dried (Na2SO4), filtered and 
concentrated. The crude was purified by flash chromatography. The H-phosphonate has to be 
stabilized, washing with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the 
purified product 45 (119 mg, 0.195 mmol, 62% yield). 
Product characterization 
Formula C30H45N2O9P 
Molecular Weight 608.66 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.19 
MS (ESI) 
Experimental m/z (%): 506.2 (70) [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.33 – 7.15 (m, 10H, Ar), 6.93 (d, J = 631.8 Hz, 1H, H-P), 6.41 (d, 
J = 8.8 Hz, 1H, NH), 5.53 (dd, J1,P = 8.4, J1,2 = 3.2 Hz, 1H, H-1), 5.11 (t, J4,3 = J4,5 = 9.7 Hz, 1H, H-4), 4. 
57 (s, 1H, ½ CH2Ph), 4.56 (s, 1H, ½ CH2Ph), 4.50 – 4.40 (m, 2H, CH2Ph), 4.37 – 4.26 (m, 1H, H-2), 
4.19 – 4.11 (m, 1H, H-5), 3.85 (t, J3,4 = 9.7 Hz, 1H, H-3), 3.50 – 3.43 (m, 2H, H-6, H-6’), 1.86 (s, 6H, 
CH3CO). 
 
31P NMR (162 MHz, CDCl3) δ (ppm) 1.87. 
 
13C NMR (101 MHz, CDCl3) δ 170.22, 169.67 (CO), 138.46, 138.07 (Cq Ar), 128.44, 128.36, 127.99, 
127.69 (CH Ar), 93.35, 93.29 (C-1), 77.96 (C-3), 73.52 (CH2Ph), 73.39 (CH2Ph), 71.00 (C-4), 70.39 (C-
5), 69.65 (C-6), 52.44, 52.39 (C-2), 23.35 (CH3CO), 20.91 (CH3CO). 
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1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
 
NHAc                       ½ H-P                     H-1 α 
“Synthesis and conjugation of Neisseria Meningitidis X Capsular Polysaccharide Fragments“ 
Experimental Section 
 
 
C
H
A
P
TE
R
 9
: 2
-A
ce
ta
m
id
o
-4
-O
-a
ce
ty
l-
3
,6
-d
i-
O
-b
en
zy
l-
2
-d
eo
xy
-α
-D
-g
lu
co
p
yr
an
o
sy
l H
yd
ro
ge
n
-p
h
o
sp
h
o
n
at
e,
 t
ri
et
h
yl
am
m
o
n
iu
m
 s
al
t 
(4
5
) 
160 
 
13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(2-acetamido-4-O-acetyl-3,6-di-
O-benzyl-2-deoxy-α-D-glucopyranosyl phosphate), triethylammonium 
salt (46) 
 
Synthetic procedure 
Donor 14 (320 mg, 0.85 mmol) and acceptor 43 (310 mg, 0.69 mmol) were treated as described in 
the General Procedure E. Compound 46 was obtained in 45% yield (253.3 mg, 0.31mmol). 
Product characterization 
Formula C41H85N3O12P 
Molecular Weight 815.89 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.31 
Optical rotation 
25
D
+ 39.47 (c = 1.4 in CHCl3) 
MS (ESI) 
Experimental m/z (%): 713.3 (100) [M]- 
HRMS (ESI) 
Experimental m/z (%): 713.24653 (100) [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.18 (m, 15H, Ar), 6.79 (d, J = 8.5 Hz, 1H, NHAc), 5.95 (t, J = 5.4 
Hz, 1H, NHCbz), 5.49 (dd, J1,P = 7.5, J1,2 = 3.5 Hz, 1H, H-1), 5.12 – 4.99 (m, 3H, H-4, CH2Ph), 4.58 (s, 
2H, CH2Ph), 4.47 – 4.37 (m, 2H, CH2Ph), 4.36 – 4.27 (m, 1H, H-2), 4.18 – 4.08 (m, 1H, H-5), 4.00 – 
3.90 (m, 2H, CH2Olinker), 3.85 (t, J3,4 = J3,2 = 9.9 Hz, 1H, H-3), 3.52 – 3.39 (m, 2H, H-6, H-6’), 3.30 – 
3.18 (m, 2H, CH2NH), 1.87 (s, 3H, CH3CO), 1.86 (s, 3H, CH3CO), 1.65 (m, 2H, CH2linker). 
 
31P NMR (162 MHz, CDCl3) δ -0.43. 
 
“Synthesis and conjugation of Neisseria Meningitidis X Capsular Polysaccharide Fragments“ 
Experimental Section 
 
 
C
H
A
P
TE
R
 9
: 3
-(
N
-C
ar
b
o
b
en
zy
lo
xy
)a
m
in
o
p
ro
p
yl
 1
-O
-(
2
-a
ce
ta
m
id
o
-4
-O
-a
ce
ty
l-
3
,6
-d
i-
O
-b
en
zy
l-
2-
d
eo
xy
-α
-D
-g
lu
co
p
yr
an
o
sy
l p
h
o
sp
h
at
e)
, 
tr
ie
th
yl
am
m
o
n
iu
m
 s
al
t 
(4
6
) 
162 
 
13C NMR (101 MHz, CDCl3) δ 170.60, 169.75 (CO), 156.66 (Cq Ar-NH), 138.45, 137.89, 136.95 (Cq 
Ar), 128.56, 128.44, 128.40, 128.10, 128.08, 128.01, 127.79, 127.69 (CH Ar), 94.66 (C-1), 77.59 (C-
3), 73.56 (CH2Ph), 73.39 (CH2Ph), 70.95 (C-4), 70.47 (C-5), 69.79 (C-6), 66.51 (CH2Ph), 63.19 
(CH2Olinker), 52.69 (C-2), 37.51 (CH2NH), 30.47 (CH2 LINKER).  
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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3-(N-Carbobenzyloxy)aminopropyl 1-O-(2-acetamido-3,6-di-O-benzyl-2-
deoxy-α-D-glucopyranosyl phosphate), triethylammonium salt (47) 
 
Synthetic procedure 
Compound 46 (60.3 mg, 0.075 mmol) was treated as described in the General Procedure C. 
Product 47 (55.32 mg, 0.073 mmol) was obtained in quantitative yield. 
Product characterization 
Formula C39H56N3O11P 
Molecular Weight 773.80 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.31 
MS (ESI) 
Experimental m/z (%): 671.3 (100) [M]- 
NMR 
1H NMR (400 MHz, MeOD) δ 7.41 – 7.20 (m, 15H, Ar), 6.70 (d, J = 9.2 Hz, 1H, NHAc), 6.00 (t, J = 5.5 
Hz, 1H, NHCbz), 5.46 (dd,  JH-1,P =7.5, JH-1,H-2 = 3.2 Hz, 1H, H-1), 5.05 (s, 2H, CH2Ph), 4.73 (q, J = 11.7 
Hz, 2H, CH2Ph), 4.51 (dd, J = 26.8, 11.8 Hz, 2H, CH2Ph), 4.28 (td, JH-2,H-3 = 9.1, JH-2,H-1 = 3.2 Hz, 1H, H-
2), 4.04 (dt, JH-4,H-5 = 8.9, JH-4,H-3 = 4.3 Hz , 1H, H-4), 4.01 – 3.91 (m, 1H, CH2O LINKER), 3.75 – 3.62 (m, 
4H, H-5, H-3, H-6, H-6’), 3.29 (dd, J = 12.1, 6.0 Hz, 2H, CH2NH LINKER), 1.91 (s, 3H, CH3CO), 1.78 – 
1.63 (m, 2H, CH2 LINKER). 
 
31P NMR (162 MHz, CDCl3) δ -0.16. 
 
13C NMR (101 MHz, CDCl3) δ 170.60 (CO), 156.66 (Cq Ar-NH), 138.79, 138.10, 137.02 (Cq Ar), 
128.64, 128.51, 128.33, 128.16, 127.95, 127.87 (CH Ar), 95.06 (C-1), 80.13 (C-3), 74.16 (CH2Ph), 
73.72 (CH2Ph), 71.76 (C-4, C-5), 70.58 (C-6), 66.57 (CH2Ph), 63.22 (CH2Olinker), 52.75 (C-2), 37.59 
(CH2NH), 30.53 (CH2 LINKER). 
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1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
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13C (101 MHz, CDCl3): 
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Thexyldimethylsilyl 2-Acetamido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranoside (52) 
 
Synthetic procedure 
Compound 40 (437 mg, 0.81 mmol) was treated as described in the General Procedure B. Product 
52 was obtained as a white solid (197 mg, 0.363 mmol, 45% yield). 
Product characterization 
Formula C30H45NO6PSi 
Molecular Weight 543.77 g/mol 
TLC conditions Rf (H/EA 1:1) 0.41 
Optical rotation 
25
D
+ 5.35 (c = 1.1 in MeOH) 
HRMS (ESI) 
Experimental m/z: 566.29067 [M+Na]+ 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 10H, Ar), 5.60 (s, 1H, NHAc), 5.02 (d, JH-1,H-2 = 7.8 Hz, 
1H, H-1), 4.79 (d, J = 11.7 Hz, 1H, ½ CH2Ph), 4.71 (d, J = 11.7 Hz, 1H, ½ CH2Ph), 4.60 (d, J = 12.0 Hz, 
1H, ½ CH2Ph), 4.56 (d, J = 12.0 Hz, 1H, ½ CH2Ph), 3.97 (dd, JH-3,H-2 = 10.2, JH-3,H-4 = 9.1 Hz, 1H, H-3), 
3.73 (d, JH-6,H-5 = JH-6’,H-5 = 4.9 Hz, 2H, H-6, H-6’), 3.66 (t, JH-4,H-3 = JH-4,H-5= 9.1 Hz, 1H, H-4), 3.51 (dt, JH-
5,H-4 = 9.1, JH-5,H-6 = JH-5,H-6’ = 4.9 Hz, 1H, H-5), 3.30 (dt, JH-2,H-3 = 10.2, JH-2,H-1 = 7.8 Hz, 1H, H-2), 1.88 
(s, 3H, CH3CO), 1.69 – 1.54 (ept, J = 6.8 Hz, 1H, CH TDS), 0.87 (d, J = 1.7 Hz, 3H, CH3 TDS), 0.85 (d, J 
= 1.7 Hz, 3H, CH3 TDS), 0.83 (d, J = 1.2 Hz, 6H, 2 CH3 TDS), 0.15 (s, 3H, CH3Si TDS), 0.12 (s, 3H, CH3Si 
TDS). 
 
13C NMR (101 MHz, CDCl3) δ 170.33 (CO), 138.91, 138.09 (Cq Ar), 128.65, 128.57, 128.19, 127.91, 
127.86, 127.77 (CH Ar), 95.21, 95.17 (C-1), 80.58 (C-3), 74.03 (CH2Ph), 73.95 (C-5), 73.86 (CH2Ph), 
73.41 (C-4), 71.05 (C-6), 59.21 (C-2), 34.23 (CH TDS), 24.96 (Cq TDS), 23.68 (CH3CO), 20.21 (CH3 
TDS), 18.68 (CH3 TDS), -1.67, -3.33 (CH3Si TDS). 
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1H (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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Thexyldimethylsilyl 2-Acetamido-3,6-di-O-benzyl-2-deoxy-4-hydrogen-
phosphonate-β-D-glucopyranosyl (53), triethylammonium salt 
 
Synthetic procedure 
Salicylchlorophosphite (110 mg, 0.543 mmol) was slowly added to a solution of the alcohol 52 (197 
mg, 0.363 mmol) in dry pyridine (1.5 mL) at 0°C. The reaction was stirred at r.t. for 1 hour. Then a 
1M solution of TEAB (4 mL/mmol) was added to the reaction mixture at r.t., and the mixture was 
diluted with CH2Cl2, washed three times with cold TEAB (0.5 M), dried (Na2SO4), filtered and 
concentrated. The crude was purified by flash chromatography. The H-phosphonate has to be 
stabilized, washing with 0.25M cold TEAB [then drying (Na2SO4), filtering and concentrating] the 
purified product 53 (154.3 mg, 0.22 mmol, 68% yield). 
Product characterization 
Formula C36H61N2O8PSi 
Molecular Weight 708.94 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.16 
Optical rotation 
25
D
+ 23.19 (c = 1.3 in MeOH) 
MS (ESI) 
Experimental m/z: 606.4 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.38 – 7.14 (m, 9H), 6.98 (d, JH-P,P = 633.6 Hz, 1H, HP), 6.28 
(d, J = 7.8 Hz, 1H, NHAc), 4.93 – 4.83 (m, 2H, ½ CH2Ph, H-1), 4.69 (d, J = 11.3 Hz, 1H, ½ CH2Ph), 4.63 
– 4.50 (m, 2H, CH2Ph), 4.23 – 4.09 (m, 1H, H-4), 4.06 – 3.90 (m, 2H, H-3, H-6), 3.75 – 3.58 (m, 3H, 
H-2, H-5, H-6’), 1.84 (s, 3H, CH3CO), 1.66 – 1.52 (ept, J = 6.8 Hz, 1H, CH TDS), 0.85 (s, 3H, CH3 TDS), 
0.84 (s, 3H), 0.82 (s, 6H, 2 CH3 TDS), 0.16 (s, 3H, CH3Si TDS), 0.13 (s, 3H, CH3Si TDS). 
31P NMR (162 MHz, CDCl3) δ (ppm) 3.46. 
13C NMR (101 MHz, CDCl3) δ 170.17 (CO), 139.17, 139.07 (Cq Ar), 128.29, 128.21, 127.56, 127.41, 
127.35 (CH Ar), 95.91 (C-1), 80.79, 80.78 (C-3), 75.34, 75.30 (C-5), 74.00 (CH2Ph), 73.46 (CH2Ph), 
73.37, 73.31 (C-4), 70.30 (C-6), 58.01 (C-2), 34.19 (CH TDS), 24.94 (Cq TDS), 23.60, 23.59 (CH3CO), 
20.20, 20.19, 18.69, 18.67 (CH3 TDS), -1.67, -3.25 (CH3Si TDS). 
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1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
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13C (101 MHz, CDCl3): 
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Thexyldimethylsilyl 2-Acetamido-3,6-di-O-benzyl-2-deoxy-β-D-
glucopyranose 4-(2-acetamido-4-O-acetyl-3,6-di-O-benzyl-α-D-
glucopyranosyl phosphate) (54), triethylammonium salt 
 
Synthetic procedure 
Donor 53 (154.3 mg, 0.22 mmol) and acceptor 43 (82 mg, 0.185 mmol) were treated as described 
in the General Procedure E. Compound 54 was obtained in 56% yield (124 mg, 0.123 mmol). 
Product characterization 
Formula C60H88N3O15PSi 
Molecular Weight 1150.4 g/mol 
TLC conditions Rf (DCM/MeOH 9:1) 0.25 
Optical rotation 
25
D
+ 33.98 (c = 0.55 in MeOH) 
HRMS (ESI) 
Experimental m/z: 1047.44387 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.02 (m, 20H, Ar), 6.93 (d, JNH,H-2B = 9.7 Hz, 1H, NHAc-B), 5.50 
(dd, JH-1B,P = 5.8, JH-B,H-2B = 3.4 Hz, 1H, H-1B), 5.23 (d, JNH,H-2A = 8.7 Hz, 1H, NHAc-A), 5.18 – 5.05 (m, 
2H, ½ CH2Ph, H-4B), 4.79 – 4.70 (m, 2H, ½ CH2Ph, H-1A), 4.65 – 4.13 (m, 9H, 3 CH2Ph, H-2B, H-5B, 
H-6A), 4.09 – 3.97 (m, 1H, H-4A), 3.86 – 3.77 (m, 1H, H-3A), 3.72 – 3.59 (m, 4H, H-3B, H-2A, H-6’A, 
H-5A), 3.53 – 3.42 (m, 2H, H-6B, H-6’B), 2.03 (s, 3H, CH3CO), 1.84 (s, 3H, CH3CONH), 1.73 (s, 3H, 
CH3CONH), 1.58 (ept, J = 6.82 Hz, 1H, CH TDS), 0.83 (s, 3H, CH3Si TDS), 0.82 (s, 3H, CH3Si TDS), 0.80 
(s, 6H, CH3Si TDS), 0.16 (s, 3H, CH3Si TDS), 0.11 (s, 3H, CH3Si TDS). 
 
31P NMR (162 MHz, CDCl3) δ (ppm) -2.52. 
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13C NMR (101 MHz, CDCl3) δ 170.78, 169.74, 169.67 (CO), 139.03, 138.88, 138.61, 138.22 (Cq Ar), 
128.58, 128.46, 128.38, 128.27, 128.16, 128.11, 127.83, 127.69, 127.57, 127.44 (CH Ar), 96.00 (C-
1A), 95.50, 95.46 (C-1B), 81.47, 81.44 (C-3A), 78.71 (C-3B), 75.83, 75.80 (C-5A), 75.19, 75.12 (C-4A), 
75.03, 73.49, 73.34, 72.99 (CH2Ph), 70.86 (C-4B), 70.66 (C-6A), 70.00 (C-6B), 69.70 (C-5B), 57.50 (C-
2A), 52.31, 52.23 (C-2B), 34.16 (CH TDS), 24.91 (Cq TDS), 23.64, 23.59 (CH3CONH), 20.93(CH3CO), 
20.16, 18.64 (CH3 TDS), -1.65, -3.30 (CH3Si TDS). 
1H (400 MHz, CDCl3): 
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31P NMR (162 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
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2-Acetamido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranose 4-(2-
acetamido-4-O-acetyl-3,6-di-O-benzyl-α-D-glucopyranosyl phosphate) 
(55), triethylammonium salt 
 
Synthetic procedure 
Compound 54 (120 mg, 0.12 mmol) was treated as described in the General Procedure A. Product 
55 was obtained as a pure-α anomer (50 mg, 0.05 mmol, white solid, 40% yield). 
Product characterization 
Formula C52H70N3O15P 
Molecular Weight 1008.10 g/mol 
TLC conditions Rf (DCM/MeOH 8:2) 0.18 
HRMS (ESI) 
Experimental m/z: 905.32394 [M]- 
NMR 
1H NMR (400 MHz, CDCl3) δ 7.50 – 7.03 (m, 20H, Ar), 7.00 (d, JNH,H-2B = 9.8 Hz, 1H, NHAc-B), 6.15 (d, 
JNH,H-2A = 9.2 Hz, 1H, NHAc-A), 5.51 (dd, JH-1B,P = 5.5, JH-1B,H-2B = 3.5 Hz, 1H, H-1B), 5.28 – 4.97 (m, 3H, 
½ CH2Ph, H-1A, H-4B), 4.79 (d, J = 12.6 Hz, 1H, ½ CH2Ph), 4.61 – 4.51 (m, 2H, CH2Ph), 4.51 – 4.33 
(m, 3H, ½ CH2Ph, ½ CH2Ph, H-2B), 4.33 – 3.92 (m, 8H, H-5B, H-5A, H-2A, ½ CH2Ph, H-6A, ½ CH2Ph, 
H-3A, H-4A), 3.72 (dd, JH-6A,H-5A = 10.8, JH-6’A,H-6A = 7.6 Hz, 1H, H-6’A), 3.56 – 3.38 (m, 3H, H-3B, H-6B, 
H-6’B), 2.07 (s, 3H, CH3CO), 1.82 (s, 3H, CH3CONH), 1.75 (s, 3H, CH3CONH). 
 
31P NMR (162 MHz, CDCl3) δ (ppm) -2.92. 
 
13C NMR (101 MHz, CDCl3) δ 170.98, 170.23, 169.65 (CO), 138.90, 138.55, 137.94 (Cq Ar), 128.67, 
128.41, 128.25, 128.09, 127.84, 127.80, 127.76, 127.49, 127.37 (CH Ar), 95.50, 95.45 (C-1B), 91.82 
(C-1A), 80.58, 80.55 (C-3A), 78.69 (C-3B), 75.88 (CH2Ph), 75.37, 75.30 (C-4A), 73.37 (CH2Ph), 73.36 
(CH2Ph), 73.12 (CH2Ph), 70.99 (C-4B), 70.91, 70.89 (C-5A), 70.40 (C-6A), 69.97 (C-6B), 69.61 (C-5B), 
53.10 (C-2A), 52.30, 52.22 (C-2B), 23.55, 23.54 (CH3CONH), 23.37, 23.36 (CH3CONH), 20.91(CH3CO). 
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1H (400 MHz, CDCl3): 
 
31P NMR (162 MHz, CDCl3): 
 
H-1 ring B      H-1 ring A 
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HETCOR 1H-13C (400 MHz, CDCl3): 
 
13C (101 MHz, CDCl3): 
  
H-1 ring B      H-1 ring A 
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